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Résumé 
INTRODUCTION: De nouvelles données indiquent que l’oxyde nitrique (NO), que l’on 
retrouve en quantité accrue au niveau du cartilage de patients atteints d’ostéoarthrose 
(OA), joue un rôle dans la production de 4-hydrynonénal (HNE) via la formation de 
péroxynitrite (ONOO-). Le HNE est considéré comme étant un des produits les plus 
réactifs de la péroxidation lipidique (LPO). Notre laboratoire a rapporté des niveaux de 
HNE plus élevés que normal dans le liquide synovial provenant de genoux de patients 
OA comparativement aux sujets normaux. Nous avions aussi démontré que le HNE peut 
induire la production des médiateurs inflammatoires et cataboliques connus pour leurs 
implications dans la dégradation du cartilage dans l’OA. Le but de la présente étude est 
de vérifier si un inhibiteur sélectif pour la NO synthétase inductible (iNOS), soit le L-NIL 
(L-N6-(L-Iminoethyl)Lysine), peut empêcher la formation du HNE via l’inhibition de la 
production du NO dans des chondrocytes de patients OA.  
MÉTHODES: Les cellules ont été traitées soit avec ou sans un générateur du NO (SIN ou 
interleukine-1beta (IL-1β)) soit avec ou sans du HNE pendant 48 h en présence ou en 
absence du L-NIL. L’expression protéique de l’iNOS et de la sous-unité de la NADPH 
oxydase (NOX), la p47 (phox), a été vérifiée par Western blot. La génération du HNE a 
été révélée par ELISA, Western blot et immunohistochimie. Les niveaux de 
prostaglandine E2 (PGE2), gluthation-s-transférase (GST) et de la MMP-13 ont été 
mesurés par des kits commerciaux. La quantité de NO a été évaluée par la méthode de 
la réaction de Griess. La mesure des niveaux d'espèces réactives d’oxygène (ROS) a été 
effectuée par fluorescence en utilisant un kit commercial.  
RÉSULTATS: Le L-NIL inhibe la stimulation de la production de NO, de HNE ainsi que 
l’expression d’iNOS au niveau protéique et de l’ARNm par IL-1β. Le L-NIL bloque aussi 
la production de HNE indépendamment de la production de NO. La production des ROS 
et l’activation de p47 (phox) ont été inhibées par L-NIL. Fait intéressant, le L-NIL 
empêche la production de la PGE2, de la cyclooxygénase-2 (COX-2) et de la MMP-13 
induite par le HNE. 
CONCLUSION: les résultats obtenus semblent démontrer l’effet bénéfique du L-NIL dans 
l’OA via la prévention de la production du HNE de manière dépendante ou indépendant 
du NO.  
 
MOTS CLÉS : Arthrose; Chondrocytes; Péroxydation Lipidique; 4-Hydroxynonénal; 
Oxyde Nitrique; Inflammation; Catabolisme; L-N6-(L-Iminoethyl)Lysine; Cartilage; 
Interleukine; Stress Oxydatif; Cible Thérapeutique; Oxyde Nitrique Synthétase 
Inductible; Espèces réactives d’Oxygène; Inhibition sélective 
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Abstract 
INTRODUCTION: Emerging evidence indicates that nitric oxide (NO), which is increased in 
osteoarthritic (OA) cartilage, plays a role in 4-hydroxynonenal (HNE) generation through 
peroxynitrite formation. HNE is considered as the most reactive product of lipid peroxidation 
(LPO). We have previously reported that HNE levels in synovial fluids are more elevated in knees 
of OA patients compared to healthy individuals. We also demonstrated that HNE induces a 
panoply of inflammatory and catabolic mediators known for their implication in OA cartilage 
degradation. The aim of the present study was to investigate the ability of inducible NO synthase 
(iNOS) inhibitor, L-NIL (L-N6-(L-Iminoethyl)Lysine), to prevent HNE generation through NO 
inhibition in human OA chondrocytes.  
METHOD: Cells and cartilage explants were treated with or without either an NO generator (SIN 
or interleukin 1beta (IL-1β)) or HNE in absence or presence of L-NIL. Protein expression of both 
iNOS and free-radical-generating NOX subunit p47 (phox) were investigated by western blot. 
iNOS mRNA detection was measured by real-time RT-PCR. HNE production was analysed by 
ELISA, Western blot and immunohistochemistry. S-nitrosylated proteins were evaluated by 
Western Blot. Prostaglandin E2 (PGE2) and metalloproteinase 13 (MMP-13) levels as well as 
glutathione S-transferase (GST) activity were each assessed with commercial kits. NO release 
was determined using improved Griess method. Reactive oxygen species (ROS) generation was 
revealed using fluorescent microscopy with the use of commercial kits.  
RESULTS: L-NIL prevented IL-1β-induced NO release, iNOS expression at protein and mRNA 
levels, S-nitrosylated proteins and HNE in a dose dependent manner after 24h of incubation. 
Interestingly, we revealed that L-NIL abolished IL-1β-induced NOX component p47phox as well 
as ROS release. The HNE-induced PGE2 release and both cyclooxygenase-2 (COX-2) and MMP-
13 expression were significantly reduced by L-NIL addition. Furthermore, L-NIL blocked the IL-
1β induced inactivation of GST, an HNE-metabolizing enzyme. Also, L-NIL prevented HNE 
induced cell death at cytotoxic levels.  
CONCLUSION: Altogether, our findings support a beneficial effect of L-NIL in OA by preventing 
LPO process in NO-dependent and/or independent mechanisms. 
 
KEYWORDS : Osteoarthritis; Chondrocyte; Lipid peroxydation; 4-Hydroxynonenal; 
Catabolism; Inflammation; Nitric Oxide; L-N6-(L-Iminoethyl)Lysine; Cartilage; 
Interleukin; Oxydative Stress; Therapeutic target; Inducible Nitric Oxide Synthase; 
Reactive Oxygen Species; Selective Inhibition 
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CHAPITER 1: Introduction 
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1.1 Articular cartilage morphology 
1.1.1 Structure and composition 
Articular cartilage is made of hyaline cartilage and is found at bone extremities(Marieb 
2005). It is both aneural and avascular, thus requiring the diffusion of nutrients 
contained within the synovial fluid as the main source of nourishment for its cells 
(Woessner Jr & Howell 1993; Eckstein et al. 2006). It is composed of an extracellular 
matrix (ECM), which is mostly composed of water (±70%), collagen (15%) and 
aggrecans (9%), as well as chondrocytes (3%), cartilage specific cells which are 
embedded in the ECM (see Figure 1)(Poole et al. 2001; Bollet & Nance 1966). The 
primary function of the articular cartilage is to provide a lubricated and even joint 
surface that enables smooth articulation (Poole et al. 2001). To do so, the cartilage 
cushions against compressive forces using hydrostatic pressurization while also 
protecting against tensile and shearing forces thanks to the presence of collagen(Marieb 
2005; Eckstein et al. 2006; Poole et al. 2001). It thus protects the subchondral bone 
against abrasions and other stress-induced damages. Hyaline cartilage has a very low 
coefficient of friction which provides joints with an almost frictionless surface during 
motion(Krishnan et al. 2003; Naka et al. 2005).  
 
Adult articular cartilage is made up of four anisotropic zones: superficial or 
tangential, middle or transitional, deep or radial and calcified zone (see Figure 
2)(Hunziker et al. 2002; Buckwalter et al. 2005). Collagen fibers are arranged in a 
complex three-dimensional network which differs depending on cartilage zone(Poole et 
al. 2001; Krishnan et al. 2003; Wu & Herzog 2002). 
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Figure 1. Articular cartilage composition 
Water accounts for 70% of articular cartilage. Of the other 30%, collagen, mostly type II, constitutes half of the 
structural components. While aggrecans represent 9% of the articular cartilages wet weight, chondrocytes only 
represent 3% (Bronner & Farach-Carson 2007). 
 
 
 
Figure 2. Structural organisation of articular cartilage  
Articular cartilage is organized into zones and is mainly composed of water, type 2 collagen, proteoglycans and 
chondrocytes. Collagen fiber orientation, proteglycan distribution and chondrocyte organization all change according 
to cartilage zone. Histologically, adult articular cartilage consists of four zones: superficial or tangential, middle or 
transitional, deep or radial and calcified zone(Buckwalter et al. 2005). The superficial surface provides a highly 
efficient lubrication mechanism with an extremely low coefficient of friction(Kumar et al. 2001). Deeper layers are 
largely responsible for the mechanical properties of the articular cartilage, especially its compressive and tensile 
properties(Kumar et al. 2001). The anisotropic structural organization of the hyaline cartilage seems to be essential 
for its functional integrity(Hunziker et al. 2002). 
Water
70%
Other, 3%
Cells, 3%
Aggrecans, 9%
Collagen, 15%Type II, 12%
Other types, 3%
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Within this network are the proteoglycans, named « aggrecans », which are negatively 
charged under physiological conditions thus making them hydrophilic and producing 
rod-like configurations called « proteoglycan aggregates » (Grodzinsky 1983). The 
mechanical properties of the articular cartilage depend on the interaction between the 
collagen network, hydrophilic proteoglycan aggregates and water(Quinn et al. 2001). 
Indeed, experiments have shown that the low hydraulic permeability and high swelling 
tendency of proteoglycans as well as their confinement within the collagen fiber 
network are responsible for the joint cartilage’s functional integrity(Poole et al. 2001).  
 
 
1.1.2 Metabolic and biochemical characteristics 
Cartilage function and integrity are both maintained by a sole cell type: the chondrocyte. 
Chondrocytes are highly differentiated cells whose primary purpose is to produce and 
maintain the ECM in articular cartilage(Muir 1995). Since cartilage is avascular, 
chondrocytes need to be able to function under very low oxygen conditions because 
concentration in deep layers can be as low as 1%(Spencer et al. 1990; Henrotin et al. 
2005). As such, chondrocytes prefer the anaerobic pathway resulting in lactate 
production even in aerobic environments(Stockwell 1979; Marcus & Sokoloff 1973). 
Chondrocytes produce a great variety of molecules to maintain articular cartilage 
homeostasis. Cytokines, such as Interleukin-1 (IL-1), Interleukin-10 (IL-10), tumour 
necrosis factor alpha (TNF-α) to name only a few, which have pro- or anti- inflammatory 
properties through many different signalling pathways are synthesized by cartilage 
cells(Iannone et al. 2000; Fernandes et al. 2002). These cells are usually long-lived, 
lasting as long as their owners, and hardly ever divide in adults even though they retain 
capacity to do so if ECM integrity is degraded(Muir 1995). 
 
The collagen produced by chondrocytes accounts for 50% to 90% of the articular 
cartilage dry weight(Muir 1995). Collagen is an extracellular protein comprised of three 
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polypeptide α-chains which each have a tripeptide sequence with glycine in every third 
position and proline or 4-hydroxyproline frequently in first and/or second 
position(Budavari 1989). These chains twist tightly into a helix; many molecules 
combine to form extended rope-like structures named « fibrils »(Muir 1995). In 
articular cartilage, type 2 collagen (Coll II) represents 80% of the collagen(Bronner & 
Farach-Carson 2007). Articular collagen has a very long half-life resulting in gradual 
changes and declined tensile strength over the years(Muir 1995). 
 
Chondrocytes also produce the aggrecans which form the proteoglycan 
aggregates found embedded in the collagen network. To form these aggregates, many 
aggrecan molecules will bind to a single chain of hyaluronan, another EMC component 
synthesized by chondrocytes (see Figure 3)(Muir 1995). The size of the proteoglycan 
aggregates is key in their immobilisation within the collagen network; bigger sized 
aggregates more effectively lodge themselves making them immovable(Muir 1995). The 
affinity of aggrecans for hyaluronan is an important factor in the size of the proteoglycan 
aggregates and is enhanced when they are processed from a low affinity form to a high 
affinity form(Sandy et al. 1989). Studies have shown that the processing of aggrecans 
slows with age(Sandy et al. 1989)  
 
Though articular cartilage has great durability, sometimes providing normal joint 
function for 80 years or more, it has a limited ability to repair itself and its capacity to 
do so decreases with age(Buckwalter et al. 2005; Buckwalter & Mankin 1998). This lack 
of an effective repair response leads to risk of progressive degeneration of the tissue in 
many individuals older than 40 years (Buckwalter et al. 2000). 
.  
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Figure 3. Articular cartilage composition 
a. Collagen network consisting of mostly type II collagen. b. Chain of hyaluronan to which aggrecans bind to 
form the proteoglycan aggregates c. Aggrecan 
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1.2 Osteoarthritis (OA) 
1.2.1 Definition and classification 
Osteoarthritis (OA), also known as degenerative arthritis or hypertrophic arthritis, is a 
degenerative joint disorder(Arden & Nevitt 2005).The American College of 
Rheumatology defines OA as an “heterogeneous group of conditions that lead to joint 
symptoms and signs which are associated with defective integrity of articular cartilage, 
in addition to related changes in the underlying bone at the joint margins.”(Bronner & 
Farach-Carson 2007). It most often affects knee, hip as well as hand joints and is mainly 
characterized by a progressive and irreversible destruction of cartilage. This causes 
joint space narrowing, secondary synovial membrane inflammation, osteophytes, 
subchondral sclerosis, formation of cysts and abnormalities around bone extremities 
(see Figure 4)(Arden & Nevitt 2005). OA can be categorized into two different types: 
either primary (or idiopathic), if its origin is not linked to a pathology (usually caused 
by aging), or secondary, if it can be associated with a specific cause such as a 
predisposing pathology(Bronner & Farach-Carson 2007). 
 
OA diagnosis is usually assessed using radiography through detection of the 
above described characteristics(Arden & Nevitt 2005; Spector et al. 1993). For almost 
fifty years, the Kellgren and Lawrence system has been used by most physicians to 
determine the severity and stage of the disease(Arden & Nevitt 2005; Spector et al. 
1993). This qualitative global grading scale characterizes OA in five grades, from 0, no 
OA, to 4, severe OA(Arden & Nevitt 2005; Schiphof et al. 2008).  
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Figure 4. Normal and osteoarthritic knee at early and late stages  
In early osteoarthritis, destruction of cartilage (1) and synovial membrane inflammation (2) can be observed. In late 
or advanced stage, pathology causes osteophyte formation (3), subchondral sclerosis (4), formation of cysts (5) and 
abnormalities around the bone extremities (6). 
 
 
 
There is currently no cure for the disease(Felson, Lawrence, Hochberg, et al. 
2000). Indeed, treatment for OA consists of managing and controlling pain to improve 
both function and quality of life while avoiding therapeutic toxicity(Felson, Lawrence, 
Hochberg, et al. 2000). The ultimate and definitive treatment when all else has failed or 
when OA is too severe is the surgical removal of the affected joint(Felson, Lawrence, 
Hochberg, et al. 2000). However this is used as a last resort since it is highly invasive, 
costly and has limited durability with patients who keep the prostatic joint for more 
than 20 years or participate in high-demand activities(Felson, Lawrence, Hochberg, et 
al. 2000). 
 
Nevertheless, research is being done to find new ways to slow or even reverse OA 
pathophysiological effects. Indeed, promising research on the use of inflammatory 
regulatory pathway decoys, such as NF-κB decoys, in rheumatoid arthritis has shown 
new potential treatment for OA (Miagkov et al. 1998; Makarov 2000). Also being 
researched is the regenerative capabilities of adipose tissue-derived stromal cells. It has 
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been shown, both in vitro and in vivo, that these cells can differentiate into chondrocytes 
and produce characteristic cartilage matrix molecules which suggest their potential in 
cartilage tissue regeneration (Awad et al. 2004; Erickson et al. 2002). 
 
1.2.2 Epidemiology of OA 
1.2.2.1 Prevalence and incidence of OA 
Even though great progress has been made in many fields regarding age- related tissue 
alteration and diseases, few has been made in articular cartilage changes caused by 
aging(Martin & Buckwalter 2002). This seems surprising since these changes can 
increase the risk of synovial joint degeneration with loss of structure and function that 
can potentially lead to OA. It affects the majority of people by age 65 (60% of men and 
70% of women) and 80% of people over 75(Buckwalter et al. 2005; Bronner & Farach-
Carson 2007; Arden & Nevitt 2005). According to the Arthritis Foundation, OA affects 
some 27 million Americans. It is the second most common diagnostic and the number 
one invalidity cause in elderly people(Peat et al. 2001). In fact, OA is the most common 
of all joint disorders and accounts for more hospitalizations than rheumatoid arthritis 
(RA) each year in the United States(Arden & Nevitt 2005). There are few age related 
diseases that impose a greater burden on the health care system as does OA(Praemer et 
al. 1992). As mentioned earlier, surgery is the only definitive treatment for OA; this 
poses a problem because of operation availability. In Canada alone, hip and knee 
replacement surgeries have more than doubled between 1996 and 2006 with a total of 
almost 69 000 in 2006(Canadian Institute for Health Information 2008). Waiting times 
for these surgeries in Canada go from 76 days to 1 year depending on the province and 
what joint needs replacing(Canadian Institute for Health Information 2006). All of these 
make OA a major socio-economic problem. Since we are faced with unprecedented rate 
of population ageing, median age is expected to increase from 26.6 years in 2000 to 37.3 
years in 2050, this problem will only get worse unless a solution is found(Arden & Nevitt 
2005; United Nations 2002; Steven et al. 2007; Lutz et al. 2008).  
 
10 
1.2.2.2 Risk factors 
Risk factors for OA are female gender, exposure to oxidants, overweight/obesity, genetic 
factors, joint injury, age, increased bone mineral density and intense physical 
activities(Bronner & Farach-Carson 2007; Arden & Nevitt 2005; Felson et al. 1997; 
Felson, Lawrence, Dieppe, et al. 2000). Surprisingly, it seems it is not the “wear and tear” 
that makes aging a risk factor since daily usage appears to have a protective effect on 
the articular cartilage(Bronner & Farach-Carson 2007). The main problem of aging 
might rather be linked to a higher rate of cellular senescence, causing problems in EMC 
replication, repair or maintenance(Bronner & Farach-Carson 2007). As mentioned 
earlier, the tensile strength of articular collagen changes and decline over the years and 
processing of aggrecans, giving them higher affinity for hyaluronan, slows with 
age(Muir 1995; Sandy et al. 1989). Joint injury, overweight/obesity and intense physical 
activities all add biomechanical stress on the articular cartilage and have been shown in 
a great number of studies to be important risk factors for knee OA(Blagojevic et al. 
2010). Unexpectedly, some studies have shown that smoking might have a small 
protective effect, though these findings are controversial and are subjects to debate 
(Blagojevic et al. 2010; Felson et al. 1989). 
 
OA’s etiopathogenesis is still relatively unclear; many concepts have been postulated 
and though biomechanics appear to play a significant role, biochemistry seems as 
important(Martin & Buckwalter 2002; Dijkgraaf et al. 1995).  
11 
1.3 Pathophysiology of OA 
Regardless of what causes it initially, OA starts with an imbalance in the synthesis and 
degradation of the ECM by chondrocytes (Dijkgraaf et al. 1995). In healthy articular 
cartilage, chondrocytes are responsible for maintaining ECM homeostasis(Martin & 
Buckwalter 2002). The anabolic functions of chondrocytes are usually controlled by 
cytokines and growth factors(Sandell & Aigner 2001). These factors include 
transforming growth factor beta (TGF-β), insulin-like growth factor I (IGF-I) and bone 
morphogenetic proteins (BMPs)(Sandell & Aigner 2001). In the beginning of OA, 
osteoarthritic cartilage shows increased water content, early loss of proteoglycans as 
well as alterations in both size and arrangement of collagen fibers(Dijkgraaf et al. 1995; 
Goldring 2000). Repair attempts lead to accelerated cartilage turnover which means 
increased cell proliferation and matrix synthesis(Dijkgraaf et al. 1995).  
 
The chondrocytes repair response is also thought to be increased: (1) by greater 
diffusion on growth factors cartilage due to its loss of integrity, (2) by release of 
previously ECM component-bound growth factors and (3) by chondrocyte upregulation 
of growth factor expression, such as IGF-1(Dijkgraaf et al. 1995). Unfortunately, as the 
pathology evolves, the increased synthesis cannot sufficiently compensate for the 
increased degradation resulting in tissue degeneration (see Figure 5)(Dijkgraaf et al. 
1995; Sandell & Aigner 2001).  
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In early OA, the cytokine/growth factor balance responsible for normal 
homeostasis is disrupted and an increase in both inflammatory and catabolic cytokines 
can be measured in OA synovial fluids(Sandell & Aigner 2001; Goldring 2000). 
Proinflammatory cytokines, such as IL-1, TNF-α, IL-17 and IL-18, are known to cause an 
important increase in proteinase activity. In OA, they are produced by two types of cells: 
activated synovial cells, leading to proinflammatory cytokine presence in synovial fluid 
thus acting on cartilage resident cells in a paracrine manner, as well as chondrocytes, 
which leads to autocrine activation(Fernandes et al. 2002; Sandell & Aigner 2001; 
Goldring 2000). They are responsible for greater matrix metalloproteinases (MMPs) 
synthesis, an increase in aggrecanases, a decrease in MMP enzyme inhibitors and in ECM 
production(Mort & Billington 2001; Henrotin et al. 2002; Dean 1991). Proinflammatory 
cytokines also induce cyclooxygenase-2 (COX2) and inducible nitric oxide synthase 
(iNOS) through nuclear factor kappa B (NFκB) activation which lead to an increased 
release of both prostaglandin E2 (PGE2) and nitric oxide (NO)(Roman-Blas & Jimenez 
2006; Amin et al. 1997). TNF-α also stimulates synthesis of phospholipase A2 (PLA2) by 
chondrocytes. 
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Figure 5. Osteoarthritis and matrix homeostasis 
In normal cartilage, chondrocytes maintain matrix homeostasis. But when joint suffers cartilage damage and/or loss 
due to one of many factors (mechanical stress, genetic factors, etc.), the fragile equilibrium between matrix synthesis 
and degradation is disrupted. This onset of OA leads to upregulation of matrix metalloproteinases (MMPs) and 
inflammatory cytokines (interleukine 1β (IL-1β), IL-17 and tumour necrosis factor-α (TNF-α)) which increases nitrous 
oxide (NO) generation(Sandell & Aigner 2001; Goldring 2000). This is followed by attempts to repair cartilage by 
increasing anabolic functions, thanks to growth factors (transforming growth factor beta (TGF-β), insulin-like growth 
factor I (IGF-I) and bone morphogenetic proteins (BMPs)) which results in type II collagen (Coll II) synthesis and 
reorganization as well as in chondrocyte proliferation(Dijkgraaf et al. 1995). Unfortunately, as OA progresses, 
anabolic functions are unable to keep up with tissue degradation. 
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1.3.1 Roles of cytokines in OA 
Proinflammatory cytokines are cell-signaling molecules that are responsible for 
inducing inflammation mediators such as iNOS, COX-2, PLA2, etc(Dinarello 2000; 
Feldmann & Saklatvala 2001). It is a widespread belief that proinflammatory cytokines 
play a crucial role in the genesis and development of OA(Poole et al. 2001; Kobayashi et 
al. 2005; Hedbom & Häuselmann 2002). There are many proinflammatory cytokines, 
including many ILs, TNFs, interferons and colony-stimulating factors, but among these, 
two appear to be most directly implicated in the pathological processes of OA, IL-1β and 
TNF-α(Dinarello 2000; Kobayashi et al. 2005). Through activation of many transcription 
factors, such as NF-κB and the activator protein (AP)-1, these two act synergistically and 
can induce synovial cells and chondrocytes to synthesize other proinflammatory 
cytokines including IL-8 and IL-6(Fernandes et al. 2002).  
 
1.3.1.1 IL-1β 
The IL-1 gene family consists of three genes: IL-1α, IL-1β and IL-1 receptor antagonist 
(IL-1Ra)(Dinarello 1996). The two former are agonists while the latter is a specific 
receptor antagonist(Dinarello 1996). IL-1α represents only about 10% of IL-1 agonist 
proteins produced by LPS-activated human monocytes and its processing and release 
remain to be understood(Feldmann & Saklatvala 2001). IL-1β accounts for about 
90%(Feldmann & Saklatvala 2001). Both exist in two forms: mature (17,5 kDa) and 
precursor (pro-IL-1α or pro-IL-1β) (31 kDa)(Fernandes et al. 2002; Goldring 2000). In 
the case of IL-1β, the mature (or active) form is generated through pro-IL-1β cleavage 
by IL-1β converting enzyme (ICE also known as caspase-1) and can be found in synovial 
membrane, synovial fluid and cartilage(Fernandes et al. 2002; Feldmann & Saklatvala 
2001).  
 
Even though there are two types of cell surface receptors (IL-1R), namely type I (IL-1RI) 
and type II (IL-1RII), it appears IL-1β induces inflammation solely as a result of its 
association to the first(Feldmann & Saklatvala 2001). Indeed, signal transduction of IL-
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1 can only be achieved through IL-1α or IL-1β binding to IL-1RI(Dinarello 1996) (see 
Figure 6a). Type II IL-1R (IL-1RII) has been described as being a “decoy” receptor for 
IL-1β since it binds IL-1β tightly but, due to a short signal transducing cytosolic domain, 
cannot lead to cell signaling(O’Neill & Dinarello 2000; Colotta et al. 1994) (see Figure 
6b). Both IL-1RI and IL-1RII can be found in soluble form (IL-1sRI and IL-1sRII) in body 
fluids(Dinarello 1996). While IL-1RI has greater affinity with IL-1α than with IL-1β, IL-
1RII binds IL-1β with a lot more affinity than IL-1α(Dinarello 1996). IL-1RII, in both 
cell-bound and soluble form, seems to be an efficient IL-1β trap due to high affinity and 
almost irreversible binding caused by a very slow dissociation rate (2 hours)(Dinarello 
1996). 
 
  An IL-1R accessory protein (IL-1R-AcP) has also been identified and seems to be 
vital to IL-1β signaling(Feldmann & Saklatvala 2001). Indeed, IL-1β signal transduction 
necessitates the formation of a IL-1RI/ IL-1R-AcP/ IL-1β complex which probably leads 
to dimerization of the IL-1RI and IL-1R-AcP cytosolic domains (see Figure 6a)(Feldmann 
& Saklatvala 2001; O’Neill & Dinarello 2000; O’Neill et al. 2003). IL-1β appears to first 
bind IL-1RI with low affinity forming a IL-1β/IL-1RI complex which allows IL-1R-AcP to 
dock to the newly formed complex whose binding affinity is now high(Dinarello 1996). 
IL-1 activation results in nuclear translocation of NF-κB and AP-1(Dinarello 2000). The 
biochemical events induced by IL-1 take place within a few minutes of its activation; 
among these is phosphorylation of PLA2 AP which leads to a rapid release of arachidonic 
acid (AA) (Dinarello 2000).  
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Figure 6. Interleukine-1beta (IL-1β) signal transduction 
a. Interleukine-1beta (IL-1β) binds its receptor, IL receptor type I (IL-1RI) with low affinity. IL-1R accessory protein (IL-
1R-AcP) then associates with the IL-1β/ IL-1RI complex with a high affinity. Formation of the IL-1RI/ IL-1R-AcP/ IL-1β 
complex leads to signal transduction through dimerization of cytosolic domains. 
b. IL-1β binds its receptor, IL receptor type II (IL-1RII) with high affinity. However, due to a short signal transducing 
cytosolic domain no signal can be transduced. 
 c. IL-1R antagonist (IL-1Ra) avidly binds to IL-1RI. IL-1R-AcP cannot associates with the IL-1Ra/ IL-1RI complex, thus 
leading to no signal transduction. 
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Another related protein is the IL-1Ra which is a natural inhibitor of IL-1(Kobayashi 
et al. 2005). It acts by binding to IL-1R without inducing signal transduction since IL-1R-
AcP cannot bind the IL-1Ra/ IL-1RI complex(Feldmann & Saklatvala 2001) (see Figure 6c). 
IL-1Ra is a soluble 22 kDa glycosylated protein which can also be found in a non-
glycosylated 17kDa form(Kobayashi et al. 2005). It is under this last form that IL-1Ra binds 
IL-1R(Dinarello 1996). IL-1Ra has 26% homology with IL-1β (which is greater than the 
homology between IL-1β and IL-1α) (Dinarello 1996). However, contrary to IL-1β, IL-1Ra 
has much more affinity with IL-1RI than with IL-1R2(Dinarello 1996). IL-1RI occupancy 
by IL-1Ra very effectively prevents IL-1 signal transduction(Dinarello 1996). 
 
1.3.1.2 TNF-α 
The TNF superfamily comprises many trimeric cytokines and cell surface proteins (at 
least 19) such as Fas Ligand (FasL), lymphotoxin-α (LTα), receptor-activator of NF-κB 
ligand (RANKL), CD40 ligand (CD40L), TNF-α, etc.(Baud & Karin 2001; Popa et al. 2007). 
In mammalian cells, the TNF superfamily plays an essential role in a broad array of 
biological processes: inflammation, cell activation, apoptosis, host defense, 
autoimmunity, etc (Keystone & Ware 2010). TNF-α can bind two structurally distinct 
receptors, type I (TNF-RI) and type II (TNF-RII)(Tracey et al. 2008). The pleiotropic 
cytokine TNF-α has a complex role in inflammation which is very similar to IL-1 since 
they share many pathways (Popa et al. 2007). In fact, both cytokines will often synergize 
for NO induction, resulting in cell death (Dinarello 2000).  
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TNFR1 activation leads to two distinct signaling pathways: the primary one 
activates both NF-κB and AP-1 through inhibitors of κB kinase (IKK) and Jun NH2-
terminal Kinase (JNK) while the second induces apoptosis in a caspase-8 and caspase-3 
manner(Baud & Karin 2001; Tracey et al. 2008). As for TNFR2, its activation always 
results NF-κB and AP-1 signaling pathways(Baud & Karin 2001). Activation of NF-κB 
suppresses the apoptosis pathway, as long as it is not compromised; thus TNF-α 
signaling will usually lead to a proinflammatory response (see Figure 8)(Tracey et al. 
2008). The extracellular domain fragments of each receptor can be shed and they are 
then said to be in soluble form: soluble TNFR-1 and -2 (sTNRF-1 and -2)(Sharma & 
Anker 2002). Though there function is yet unknown, at high concentrations, sTNFRs 
inhibit TNF activity as they trap TNF-α(Sharma & Anker 2002). 
 
1.3.1.3 Other proinflammatory cytokines 
Many other proinflammatory cytokines have been described and are thought to play a 
role in OA, namely IL-8, IL-17 and IL-18(Fernandes et al. 2002). All three enhance matrix 
degradation and ROS generation through either upregulation of IL-1β and/or TNF-α or 
suppression of aggrecan synthesis(Fernandes et al. 2002; Bronner & Farach-Carson 
2007). IL-6 also seems to play a role in OA as it causes an increase in IL-1Ra, sTNFR, and 
tissue inhibitor of metalloproteins (TIMP) as well as enhances immune cell function and 
inflammation(Bronner & Farach-Carson 2007) [. On the other hand, when IL-6 interacts 
with its soluble receptor (sIL-6R), it leads to upregulation of MMPs and A disintegrin 
and metalloprotease with thrombospondin motifs (ADAMTS)  as well as downregulation 
of Coll II gene (COL2A1) and aggrecan(Bronner & Farach-Carson 2007).  
  
19 
 
Figure 7. Tumor Necrosis Factor-α (TNF-α) signal transduction 
Tumor Necrosis Factor-α (TNF-α) can bind either TNF Receptor 1 (TNFRI) or 2 (TNFRII).  
TNFRI activation induces to the Caspase proteolytic cascade through activation of Caspase 8 which leads in 
Cytochrome-C (CytoC) release and activation of Apoptotic Protease Activating Factor-1 (APAF-1). In turn, APAF-1 will 
recruit Caspase 9 and activate Caspase 3 which ultimately results in apoptosis. TNFRI activation also activates Jun 
NH2-terminal Kinase -1 (JUNK1), Mitogen-Activated Protein Kinases (MAPK) p38 and Extracellular signal-Regulated 
Kinases (ERK) and Nuclear Factor –KappaB (NF-κB); all of these result in a proinflammatory response (Activation of 
Metalloproteinases (MMPs), induction on inducible Nitrous Oxide (iNOS), cyclooxygenase-2 (COX-2) and many 
protinflammatory cytokines). The proinflammatory response suppresses cell death. TNFRII activation always leads to 
the proinflammatory response(Baud & Karin 2001; Popa et al. 2007; Keystone & Ware 2010; Tracey et al. 2008; 
Sharma & Anker 2002). 
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1.3.1.4 NF-κB pathway 
The NF-κB family of transcription factors play a central role in the signaling pathways 
of stress-induced apoptosis, inflammation and immune signaling through innate and 
adaptive immune responses(Roman-Blas & Jimenez 2006). This family has five 
members that associate to form a variety of homo- and hetero- dimers: RelA (p65), 
ReloB, c-Rel, NF-κB1 (p50/p105) and NF-κB2 (p52/p100)(Roman-Blas & Jimenez 2006; 
Tak & Firestein 2001). The RelA (p65) and NF-κB1 (p50/p105) heterodimer is the most 
widespread activated form of NF-κB(Tak & Firestein 2001).  
 
In OA, it mediates key events in the inflammatory response by chondrocytes. These 
events eventually lead to the progressive ECM destruction characteristic of OA(Agarwal et 
al. 2004). NF-κB is known to regulate more than 150 genes; these include genes encoding 
cytokines, for example TNF-α, IL-1β and IL-6, inducible enzymes, such as COX-2 and iNOS, 
and both pro- and anti- apoptotic molecules(Roman-Blas & Jimenez 2006). It is present in 
the cytoplasm in an inactive form(Roman-Blas & Jimenez 2006; Tak & Firestein 2001). In 
this state, the NF-κB dimer is associated with regulatory proteins known as inhibitors of κB 
(IκB): IκBα, IκBβ, IκBε and IκBγ(Roman-Blas & Jimenez 2006). NF-κB can be activated by 
many stimuli, but in OA, the most significant ones are cytokines, including TNF-α and IL-1β, 
and free radicals(Roman-Blas & Jimenez 2006). These trigger signalling pathways that 
ultimately lead IκB phosphorylation by IKK(Roman-Blas & Jimenez 2006; Tak & Firestein 
2001). Though the exact mechanism through which the IKK complex is activated by 
cytokines remains unknown, when activated, IKK initiates IκBα phosphorylation at specific 
serine residues(Roman-Blas & Jimenez 2006; Tak & Firestein 2001). NF-κBs nuclear 
localization signal is the revealed and the dimers are then free to translocate into the 
nucleus, to bind to κB enhancer elements of target genes and stimulate gene transcription 
(see Figure 8) (Roman-Blas & Jimenez 2006; Tak & Firestein 2001).  
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NF-κB is implicated in many inflammatory diseases such as OA, multiple sclerosis, 
asthma, type 2 diabetes, etc(Roman-Blas & Jimenez 2006). In OA patients, IKK is 
constitutively expressed and its activation by TNF-α and IL-1β is crucial for NF-κB 
mediated cytokine, collagenase, iNOS and COX-2 and induction(Roman-Blas & Jimenez 
2006; Tak & Firestein 2001).  
 
Thought NF-κB activation through IL-1β and TNF-α activation is well known, it 
has been shown that biomechanical signals can be converted into biochemical signals 
by cells and therefore also activate NF-κB(Agarwal et al. 2004). In experiments 
conducted with rabbit articular cartilage grown on flexible membranes, it has been 
shown that high magnitude cyclic tensile strain (15-18% equibiaxial strain) have the 
same effect on NF-κB activation than IL-1β since it induced rapid NF-κB p50-p65 
heterodimer nuclear translocation, thus upregulating proinflammatory gene 
expression, matrix degradation and decreasing matrix synthesis(Agarwal et al. 2004). 
NF-κB is also known to be redox-sensitive(Henrotin et al. 2003).  
Taking into account that 
 
OA is an age-related disease; chondrocyte senescence leads to mitochondrial 
degeneration, therefore to an increase in free radical production, such as superoxide 
anion (O2•) thus adding redox stress to the articular joint. On the other hand, mechanical 
strain in known to be an important risk factor for OA. This indicates that both redox and 
biomechanical signal activation pathways may greatly contribute in OA 
pathogenesis(Martin & Buckwalter 2002).  
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Figure 8. Nuclear factor-kappaB (NF-κB) cytokine activated pathway 
Proinflammatory cytokines bind to their receptors which lead to an unknown signal transduction that result in 
inhibitors of κB kinase (IKK) activation through its phosphorylation. IKK activation initiates inhibitors of κB (IκB) 
phosphorylation which releases NF-κB dimer. NF-κB then translocates into the nucleus to stimulate gene 
transcription (Activation of Metalloproteinases (MMPs), induction on inducible Nitric Oxide (iNOS), cyclooxygenase-
2 (COX-2) and many protinflammatory cytokines)(Dean 1991; Sharma & Anker 2002). 
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1.3.1.5 COX-2 and PGE2 
Cyclooxygenase (COX) is the enzyme responsible for prostaglandin (PG) synthesis. Also 
called prostaglandin H2 synthase (PGHS), COX converts AA into prostaglandins G2 
(PGG2), then PGH2 that can subsequently be converted to a variety of eicosanoids, more 
specifically prostanoids, which include PGE2, PGF2a, PGI2 and thromboxane (TX) A2 (see 
Figure 9)(Vane et al. 1998; Cryer & Feldman 1998). Though it was long thought that COX 
existed in only one form, two COX isoforms exist: COX-1 and COX-2(Dubois et al. 1998). 
Both have the same enzymatic activity and are very similar in structure(Vane et al. 
1998). What differentiates the two is that the first is constitutive and present in almost 
all type of cells while the latter is inducible and normally absent from cells(Dubois et al. 
1998). Therefore COX-1 is responsible of producing homeostatic levels of PGs allowing 
regulation of physiological effects such as platelet aggregation (blood clot 
formation)(Dubois et al. 1998). Synthesis of COX-2 can be stimulated by a great number 
of growth factors and proinflammatory cytokines, such as IL-1β and TNF-α, through NF-
κB inhibition(Amin et al. 1997; Gupta & DuBois 2001). In fact, PGs most important action 
is their role in inflammation; more importantly, PGE2 release is a key event in the 
swelling/redness, pain and fever caused by inflammation(Clària 2003). COX-2 has been 
shown to be responsible for PG synthesis in inflamed joint tissues and its induction has 
been observed in OA cartilage and synovial tissue(Clària 2003). These observations that 
have led searchers to investigate COX-2 selective inhibitors as an anti-inflammatory 
treatment in OA (Clària 2003).  
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Figure 9. Diagram of cyclooxygenase (COX) role in eicosanoid metabolism 
Formation of prostaglandin (PG) from arachidonic acid. Cyclooxygenase (COX) -1 and -2 oxygenate arachidonic acid 
to form PGG2 which will be reduced to PGH2. PGH2 will then be transformed into various prostaglandins by their 
respective synthase(Vane et al. 1998). 
 
 
 
1.3.2 Matrix metalloproteinases (MMPs) and aggrecanases 
MMPs are a family of degradative enzymes which target ECM components and are 
believed to have a central role in tissue remodelling and repair but, when in excessive 
expression or in lack of inhibition, they are thought to greatly contribute to OA 
pathogenesis(Sandell & Aigner 2001; Shapiro 1998). They are produced in an pro-
enzyme form and are activated by a proteolytic cleavage by cell surface associated 
plasmin or by other MMPs(Knäuper et al. 1996; MURPHY et al. 1999). There are many 
MMPs, such as 1,2,3,7,8,13 and 14, only to name a few, and they consist of different 
collagenases, stromelysins, gelatinases and matrilysin(Shapiro 1998; Shlopov et al. 
1997).  
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In OA, levels of MMP-3 (a stromelysin) MMP-1, MMP-8 and MMP-13 (all three 
collagenases) are elevated (Sandell & Aigner 2001; Goldring 2000; Shlopov et al. 1997). 
In fact, though all three collagenases seem to play a key role in OA, Coll II degradation 
seems to be mainly caused by MMP-13(Shlopov et al. 1997; Billinghurst et al. 1997). IL-
1β stimulation can enhance MMP-13 transcription because of the parallel activation of 
kinase cascades regulating NF-κB and AP-1(Tak & Firestein 2001). MMP-3 is 
responsible for degrading many ECM molecules, including proteoglycan and Coll 
II(Takahashi et al. 1999). 
 
Some enzymes, named « aggrecanases », are responsible of aggrecan proteolytic 
degradation; it is the case of some members of the ADAMTS family namely ADAMTS-4 
(also known as aggrecanase-1) and ADAMTS-5 (aggrecanase-2). Although both 
ADAMTS-4 and ADAMTS-5 can degrade aggrecans and affect articular cartilage 
integrity, studies with ADAMTS-4 and/or -5 knock-out mice seem to show that only the 
latter is associated with increased susceptibility to OA(Tang 2001; Majumdar et al. 
2007; Glasson et al. 2004; Glasson et al. 2005).  
 
The activation of MMPs can be inhibited by TIMPs. TIMPs do so by forming a high 
affinity complex(Pelletier et al. 1990). It seems that conditions in OA tissues favor MMP 
synthesis and activation over inhibition. Indeed, a lack of sufficient TIMP to counter 
increased MMP production might be a contributing factor in OA articular cartilage 
degradation(Pelletier et al. 1990). 
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1.3.3 Reactive oxygen species (ROS) 
Cytokines as well as mechanical stress can both stimulate reactive oxygen species (ROS) 
production by chondrocytes(Henrotin et al. 2005). ROS interact strongly and quickly 
with many molecules, both organic and inorganic, irreversibly changing or even 
destroying them(Bedard & Krause 2007). These include various proteins, lipids and 
nucleic acid(Bedard & Krause 2007). O2- and NO are the two main ROS generated by 
articular cartilage cells(Henrotin et al. 2005). Members of the nicotinamide adenine 
dinucleotide phosphate (NADPH) Oxidase (NOX) family reduce oxygen (O2) to O2- 
making them big ROS producers(Bedard & Krause 2007). Both IL-1β and NO can activate 
NOX(Kaur et al. 2004). O2- and NO play an important role in pathophysiology since 
derivative radicals such as hydrogen peroxide (H2O2) and proxynitrite (ONOO-) as well 
as hydroxyl radical (OH-) are created when in presence of iron(Henrotin et al. 2003; 
Henrotin et al. 2005). In OA, production of ROS is such that antioxidants capacity to 
detoxify them is insufficient, causing oxidative stress to articular cartilage, thus 
damaging it. ROS have been shown to be involved in cartilage degradation through 
intracellular signaling regulation and through direct attack of ECM molecules, 
proteoglycan and collagen molecules in particular(Henrotin et al. 2003). Various 
transcription factors, including NF-κB, are redox-sensitive through modification of 
conserved cysteines(Henrotin et al. 2003). ROS can also modify protein degradation by 
inhibiting the ubiquitin pathway(Henrotin et al. 2003). One family of ROS which has 
been shown to be very implicated in OA is the reactive nitrogen species (RNS) family. 
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1.3.4 Nitric oxide (NO) and inducible NO synthase (iNOS) 
RNS formation in chondrocytes starts with NO which will then lead to ONOO- (Henrotin 
et al. 2005)[17]. NO is synthesized by its enzyme, NO synthase (NOS), which has three 
isoforms, neuronal NOS (nNOS), endothelial NOS (eNOS) and inducile NOS (iNOS) 
(Henrotin et al. 2005). Only the two latter are present in chondrocytes. While eNOS is 
expressed constitutively, iNOS is, as its name suggests, an inducible form. As for ROS 
stimulation, iNOS expression can be induced by either mechanical stress or 
cytokines(Henrotin et al. 2005). Since OA is characterized by an overproduction of 
cytokines and an increase in mechanical stress at the articular cartilage level, it is not 
surprising that many studies has shown increased levels of iNOS in OA cartilage when 
compared to normal cartilage(Pelletier et al. 2001). Indeed, OA cartilage produce large 
amounts of NO(Henrotin et al. 2005; Henrotin et al. 2003; Pelletier et al. 2001; Pelletier 
et al. 1998). NO combines with O2- to form ONOO-(Henrotin et al. 2005). NO and ONOO- 
play an important role in OA. They affect cartilage matrix synthesis by being responsible 
for inhibition of aggrecan and COLL II synthesis and they increase the IL-1β inhibitory 
effect on EMC component synthesis(Henrotin et al. 2003). They also contribute to 
cartilage matrix breakdown by inducing chondrocyte apoptosis, increasing MMP-3 and 
MMP-13 mRNA levels in chondrocytes while inhibiting TIMPs(Henrotin et al. 2003). 
Since they upregulate proinflammatory cytokines, their production causes an 
amplification of cartilage catabolism, and all subsequent problems such as 
inflammation, swelling and pain, through a feedback loop (see Figure 10)(Pelletier et al. 
2001).  
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Figure 10. Role of inducible nitric oxide synthase (iNOS) in OA 
Proinflammatory cytokines lead to inducible nitric oxide synthase (iNOS) expression. iNOS stimulates reactive oxygen 
species (ROS) production such as nitric oxide (NO), superoxide anion (O2-) and proxynitrite (ONOO-)(Henrotin et al. 
2003). NO, O2- and ONOO- contribute to cartilage matrix degradation by inhibiting aggrecan and type II collagen (COLL 
II) synthesis, increasing the interleukine-1β (IL-1β) inhibitory effect on matrix component synthesis, inducing 
chondrocyte apoptosis, increasing metalloproteinase (MMP)-3 and MMP-13 mRNA levels in chondrocytes while 
inhibiting tissue inhibitor of metalloprotease (TIMPs) (Henrotin et al. 2003). They also upregulate proinflammatory 
cytokines, which causes an amplification of cartilage catabolism, and stimulate lipidic peroxidation of cell 
membrane(Pelletier et al. 2001; Halliwell & Chirico 1993).  
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The iNOS enzyme itself might also contribute to ROS formation. Indeed, limitation 
of substrate availability leads to uncoupling of NOS and ultimately to ROS formation 
(Gielis et al. 2011). When NOS is in its uncoupled form, electron transfer can result 
reduction of molecular oxygen, and NO which can react together to form ONOO- (Griffith 
& Stuehr 1995). ONOO- is also known for lipid peroxidation (LPO) of the cell membrane, 
composed of polyunsaturated fatty acids (PUFAs)(Radi et al. 1991). LPO produces lipid 
peroxides through a free radical chain reaction which will in turn be decomposed to 
produce epoxides, ketones, acids and aldehydes (see Figure 11 and Figure 12) (Halliwell 
& Chirico 1993).  
 
1.4 4-Hydroxynonenal (HNE) 
1.4.1 Synthesis and characteristics of HNE 
One of the many effects of oxidative stress caused by the ROS and RNS family is LPO of 
the polyunsaturated fatty acids contained in the cell’s membrane (Radi et al. 1991). The 
cell membrane is a lipid bilayer whose main function is to control the metabolite and 
electrolyte concentration gradient between the cell and it’s surrounding through 
modulation of the membrane’s permeability. Lipid damage can thus affect these 
gradients and affect cell function(Hogg & Kalyanaraman 1999). Of course, cells have the 
ability to repair or replace damaged lipids, but since LPO is a rapid chain reaction, 
normal lipid turnover can be insufficient(Hogg & Kalyanaraman 1999). Moreover, 
products of LPO, such as hydroperoxides (LOOH), alcohols and aldehydes can affect both 
cellular functions and protein expression [88]. PUFAs, such as arachidonic acid, are 
more sensitive to oxidation because their methylene hydrogens are more susceptible to 
hydrogen abstraction by ROS and RNS than those from saturated lipids(Hogg & 
Kalyanaraman 1999).  
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Figure 11. Molecular equations of lipidic peroxidation 
Overview of aldehyde generation through lipidic peroxidation (Hogg & Kalyanaraman 1999; Herdegen & Delgado-
Garcia 2004).  
 
 
 
Equations 1 and 2 show how ONOO- and •OH remove hydrogen from unsaturated 
lipids (LH) to form a lipid radical (L•)(Hogg & Kalyanaraman 1999; Herdegen & 
Delgado-Garcia 2004). The lipid radical produced subsequently reacts with oxygen to 
generate a lipid peroxyl radical (LOO•), which is key to the propagation of LPO through 
the cell membrane (eq.3) (Hogg & Kalyanaraman 1999). The lipid peroxyl radical 
produced will then remove a hydrogen to the neighboring unsaturated lipid to 
regenerate a lipid radical, which will lead to the LPO chain reaction, and LOOH which, 
due to its unstableness, will quickly fragment into reactive aldehydes (eq. 4) (see Figure 
11 and Figure 12)(Hogg & Kalyanaraman 1999). Aldehydes produced by LPO are 
believed to be the main culprits in cell damages caused by oxidative stress(Esterbauer 
et al. 1991). Because aldehydes are more stable than free radicals, they can diffuse in 
and out of cells and target cells and structures far from their point of origin(Dalle-Donne 
et al. 2006). In these cases, aldehydes are secondary messengers to primary 
reactions(Dalle-Donne et al. 2006). The most important aldehydes generated by LPO are 
LH + ONOO- → L• + [ONOOH] → L• + NO2 + •OH
LH + •OH → L• + H2O
L• + O2 → LOO•
LOO• + LH →  [LOOH] + L• →  ALDEHYDES +   L• 
Chain reaction
(1)
(2)
(3)
(4)
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malondialdehyde (MDA) and 4-Hydroxynonenal (HNE), the former being the most 
abundant lipid aldehyde while the latter is the one who which is most responsible for 
the cytopathologic effects of oxidative stress(Uchida 1999). As many other aldehydes, 
these two can react with various biomolecules such as phospholipids, proteins and even 
ribonucleic and deoxyribonucleic acids (RNA and DNA)(Dalle-Donne et al. 2006). 
 
HNE is an amphiphilic compound since it has both hydrophilic and lipophilic 
properties, though it has greater affinity for lipids than for water(Poli et al. 2008). It is 
known as a highly reactive molecule due to its three functional groups: a hydroxyl group 
(OH), a carbon-carbon (CC) double bond as well as a carbonyl group (CO) (see Figure 
13)(Poli et al. 2008). Together, these three groups frequently act synergistically so that 
HNE can react to a great number of biomolecules, especially those with amino residues 
(cysteine, lysine, histidine and rarely arginine) or thiol groups.   
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Figure 12. Lipid peroxidation 
Lipid peroxidation is a chain reaction in which a reactive oxygen (or nitrogen) species react with unsaturated lipids  
of the cell membrane and produce reactive aldehydes (adapted from Tim Vickers/ Wikimedia Commons / CC-BY-SA-3.0). 
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Figure 13. 4-Hydroxynonenal (HNE) molecule 
The HNE molecule has three functional groups : a. a hydroxyl group (OH), b. a CC double bond and c. CO carbonyl 
group(Poli et al. 2008). 
 
 
 
1.4.2 HNE adducts and target proteins 
Important reactions for HNE’s biochemical effects, as well as its metabolism, are Schiff 
base formation and Michael additions (see Figure 14) (Schaur 2003). Interaction 
between HNE and cell proteins has often been described; many HNE-binding proteins 
have been found, including heat shock proteins 72 and 90 (Hsp-72 & Hsp-90), CytoC, 
Ca2+ ATPase, albumin and many more (Carbone et al. 2004; Carbone et al. 2005; Isom et 
al. 2004; Akaishi et al. 2004; Aldini et al. 2006; Moreau et al. 2005). In addition, growing 
evidence supports a role for HNE as a physiologic modulator of signal transduction and 
of posttranslational modification(Poli et al. 2008). Our laboratory has also shown HNE’s 
ability to induce transcriptional and posttranscriptional modifications of MMP-13 and 
Coll II(Morquette et al. 2006).  
OH
O
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Figure 14. 4-Hydroxynonenal (HNE) common reactions 
a. Formation of Schiff base is made possible by HNE’s carbonyl base(Poli et al. 2008; Schaur 2003). b. Michael addition 
reaction between thiol or amino group and the CC double bond in HNE(Poli et al. 2008; Schaur 2003) (adapted from 
Poli and al. (2008). Fig 1 & 2). 
 
HNE can be found in healthy human organs in small concentration but elevated 
HNE levels has been detected in a great number of human diseases ranging from 
Alzheimer’s disease to Multiple sclerosis(Poli et al. 2008). Increased evidence suggests 
its significance in the pathogenesis of major human chronic diseases(Poli et al. 2008). 
Previous studies have linked HNE to OA by showing higher concentrations of HNE in 
chondrocytes and synovial fluid of OA patients when compared to healthy 
individuals(Morquette et al. 2006; Vaillancourt et al. 2007). In OA, HNE can be found in 
either protein-adduct form, such as with Coll II, or in free form (see Figure 
15)(Morquette et al. 2006; Vaillancourt et al. 2007). It is thought that protein 
modification is the most likely one if not the main mechanism by which HNE can 
modulate physiological and pathophysiological processes(Poli et al. 2008).  
OH
O
OH
b. Michael addition
SH (or NH)
R
O
+ R-SH (thiol)
or
+ R-NH2 (amino)
a. Schiff base formation
OH
O
OH
RN+ R-NH2 (amino)
- H2O
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Figure 15. Effect of 4-Hydroxynonenal (HNE) signalling on cell function 
Free-form and/or protein-bound HNE lead to activation of different signalling pathways therefore to production of 
cyclooxygenase-2 (COX-2), pro-inflammatory cytokines, metalloproteinases (MMPs), inducible nitric oxide synthase 
(iNOS), etc. 
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1.4.3 Metabolism of HNE 
Because HNE is toxic and normally found, in low levels, in many human cells, there exist 
multiple pathways that can metabolize it. There are three main pathways the organism 
use to detoxify HNE: reduction by alcohol dehydrogenase or aldose reductase to 1,4-
dihydroxynonene (DHN), oxidation by aldehyde dehydrogenases to form 
hydroxynonenoic acid (HNA) and conjugation with glutathione (GSH) by glutathione S-
transferase (GST) (see Figure 16) (Poli et al. 2008; Pappa et al. 2003). GST isoenzyme 
GST4A-4 has a high specificity for HNE and plays an important role in protection against 
oxidative damage(Gallagher et al. 2006; Awasthi 2006; Vaillancourt et al. 2008). 
Another molecule that might be of significant importance in decreasing HNE toxicity is 
carnosine. Studies have shown it traps HNE by forming a stable covalent adduct thus 
inhibiting its ability to bind other proteins and activate metabolic pathways(El-Bikai et 
al. 2010; Poli et al. 2008). It has been suggested that carnosine might react with HNE by 
mimicking the preferred HNE addition sites in proteins(Aldini et al. 2002).  
 
Though HNE is metabolized at a very rapid rate, it can still play an important role 
in protein modification as it activates a number of signaling pathways; more so when 
concentrations are elevated it as is the case in many pathologies(Poli et al. 2008).  That 
is why novel ways to decrease HNE levels have and are being studied around the globe. 
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Figure 16. 4-Hydroxynonenal (HNE) metabolism 
HNE’s main metabolic pathways(Poli et al. 2008; Pappa et al. 2003) (adapted from Pappa and al. (2003) Scheme 1). 
 
 
1.4.4 HNE and signalling pathways 
It was long thought that HNE’s biological and pathological effects where purely the 
result of protein modifications in cells and their environments. It has since been shown 
that HNE’s role in pathophysiology is also greatly attributable to its ability to activate 
several signalling pathways(Esterbauer et al. 1991; Esterbauer et al. 1992; Benderdour 
et al. 2003; Morquette et al. 2006; Vaillancourt et al. 2007). Indeed, HNE has been linked 
to MAPK, JNKs and caspase pathways, to name only a few (Parola et al. 1998; Poli et al. 
2008). These have many effects on cell activity as the pathways activated by HNE lead 
to cell stress and ultimately to apoptosis(Vaillancourt et al. 2008). At non-toxic levels, 
HNE can interact with histidine residues in JNKs which causes both their nuclear 
translocation and their activation(Parola et al. 1998). The activity and expression of key 
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inflammatory mediators are regulated by JNKs and p38 MAPK pathways through AP-1 
activation(Herlaar & Brown 1999). These inflammation mediators include COX-2, 
cytokines such as TNF-α and IL-1β as well as proteases such as MMP-2, MMP-9 and 
MMP-13.  
 
Also important is HNE’s inhibitory effect on the NF-κB pathway. Some studies 
have shown that HNE binds to IκB blocking its phosphorylation and subsequently 
preventing NF-κB’s translocation into the nuclei; greatly downregulating expression of 
NF-κB regulated genes(Leonarduzzi et al. 2004). In human OA chondrocytes, treatment 
with HNE appears to block selectively the NF-κB-regulated iNOS expression through 
IKKα inactivation by HNE/IKKα adducts formation(Vaillancourt et al. 2007). Poli and al. 
have suggested this might sustain inflammation and further lead to tissue degeneration 
by interfering with the immune response(Poli et al. 2008). 
 
1.5 Inducible nitric oxide synthase (iNOS) inhibitors 
To produce NO, NOS enzymes proceed to the oxidation of a nitrogen on the amino acid 
L-arginine (see Figure 17)(Fukuto & Chaudhuri 1995). This has led to research for NOS 
inhibitors using structural analogs of L-arginine since these analogs would compete 
with L-arginine binding to the enzyme(Furfine et al. 1993; Moore & Webber 1994; Misko 
et al. 1993; Marletta 1994). 
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Figure 17. Nitric oxide (NO) synthesis by nitric oxide synthase (NOS) 
Oxidation of L-arginine into L-citrulline by nitric oxide synthase (NOS) to generate nitric oxide (NO) (adapted from 
Fukuto and al., 1995 and NEUROtiker/ Wikimedia Commons / CC-BY-SA-3.0)(Fukuto & Chaudhuri 1995). 
 
 
 
1.5.1 L-N6- (l-iminoethyl)lysine (L-NIL) 
Some of the analogs tested were NG-monomethyl-L-arginine (L-NMA), NG-nitro-
L-arginine (L-NNA) and L-N6-(l-iminoethyl)lysine (L-NIL) (see Figure 18)(Furfine et al. 
1993; Moore & Webber 1994). L-NMA and L-NNA both inhibited NO synthesis but their 
use showed a marked and sustained increase in blood pressure indicating they were 
inhibiting the constitutive version of NOS(Rees 1989; Marletta 1994). Since NO plays an 
important role in normal physiology, it is crucial that a NOS inhibitor be specific to the 
inducible form in order to have potential clinical use against pathological 
overproduction of NO(Moore & Webber 1994). L-NIL was shown to have great 
selectivity for iNOS because of differences in the L-arginine binding sites of the different 
forms of NOS(Moore & Webber 1994). Some researchers have taken advantage of L-NIL 
specificity to study the role of iNOS in the pathophysiology/pathogenesis of OA both in 
vitro and in vivo(Pelletier et al. 1998; Pelletier et al. 1999; Pelletier et al. 2000; Walker 
et al. 2000; Hansel et al. 2003). Used on an experimental canine OA model, oral 
administration of L-NIL has attenuated OA progression and reduced cartilage matrix 
brakedown(Pelletier et al. 1998). 
Nitric oxide synthetase 
L-arginine L-citrulline
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Figure 18. L-arginine analogs 
Molecular structures of L-arginine, NG-monomethyl-L-arginine (L-NMA), NG-nitro-L-arginine (L-NNA) and L-N6- (l-
iminoethyl)lysine (L-NIL) (adapted from Moore and al., 1994 and NEUROtiker/ Wikimedia Commons / CC-BY-SA-
3.0)(Moore & Webber 1994). 
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1.6 Objectives and hypothesis 
Our lab has been investigating HNEs the pathophysiological role of HNE in OA for a few 
years now. Our research group was the first to report the involvement of HNE in the 
degradation and destruction of cartilage in OA through its ability to induce 
transcriptional and posttranslational modifications of Coll II and MMP-13, its capacity 
to induce cell death as well as its selective upregulation of COX2 expression(Morquette 
et al. 2006; Vaillancourt et al. 2007; Vaillancourt et al. 2008). We have studied it both in 
vitro and in vivo and have proven its importance in the pathogenesis of OA(Morquette 
et al. 2006; Shi et al. 2014; El-Bikai et al. 2010).  
 
 Because NO plays such a crucial role in LPO through both its derivative ONOO- 
and its ability to generate ROS through NOX activation and since its main source in OA 
tissues is iNOS, we hypothesized that selectively inhibiting iNOS would protect against 
LPO, more specifically, that it would reduce HNE production. 
 
Therefore, the aim of the present study was to investigate the ability of iNOS inhibitor, 
L-NIL, to prevent LPO product generation through NO inhibition in human OA 
chondrocytes. 
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2.1 Abstract 
 
Nitric oxide (NO) and the lipid peroxidation (LPO) product 4-hydroxynonenal (HNE) are 
considered to be key mediators of cartilage destruction in osteoarthritis (OA). NO is also 
known to be an important intermediary in LPO initiation through peroxynitrite 
formation. The aim of the present study was to assess the ability of the inducible NO 
synthase (iNOS) inhibitor N-iminoethyl-L-lysine (L-NIL) to prevent HNE generation via 
NO suppression in human OA chondrocytes and cartilage explants. Human OA 
chondrocytes and cartilage explants were treated with L-NIL and thereafter with or 
without interleukin-1beta (IL-1β) or HNE at cytotoxic or non-cytotoxic concentrations. 
Parameters related to oxidative stress, apoptosis, inflammation and catabolism were 
investigated. L-NIL stifled IL-1β-induced NO release, iNOS activity, nitrated proteins and 
HNE generation in a dose-dependent manner. It also blocked IL-1β-induced inactivation 
of the HNE-metabolizing glutathione-s-transferase (GST). L-NIL restored both HNE and 
GSTA4-4 levels in OA cartilage explants. Interestingly, it also abolished IL-1β-evoked 
reactive oxygen species (ROS) generation and p47 NADPH oxidase activation. 
Furthermore, L-NIL significantly attenuated cell death and markers of apoptosis elicited 
by exposure to a cytotoxic dose of HNE as well as the release of prostaglandin E2 and 
metalloproteinase-13 induced by a non-cytotoxic dose of HNE. Altogether, our findings 
support a beneficial effect of L-NIL in OA by (i) preventing the LPO process and ROS 
production via NO-dependent and/or -independent mechanisms and (ii) attenuating 
HNE-induced cell death and different mediators of cartilage damage. 
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2.2 Introduction 
Nitric oxide (NO) is a free radical that undergoes a variety of reactions in tissues with 
other radicals, such as superoxide or molecular oxygen, leading to the generation of 
highly-damaging nitrosating species [Squadrito and Pryor, 1998]. It has also been 
shown to cause nitrosation or oxidation of zinc finger-containing proteins involved in 
DNA repair [Sidorkina et al., 2003]. Furthermore, in vitro and in vivo cell exposure to 
NO from donor drugs can modulate the activity of mitochondrial enzymes, 
metalloproteinases (MMPs) and protein kinases via a nitrosylation process [Gu et al., 
2002;Gu et al., 2010]. NO overproduction damages cellular components, including 
lipids, which results in declining physiological function and cell death. NO reaction with 
lipids generates lipid peroxidation (LPO), giving rise to 4-hydroxynonenal (HNE) 
[Morquette et al., 2006]. LPO initiation by NO in biological systems requires the 
generation of superoxide anion and hydroxyl radicals [Carrico et al., 2009;Szabo and 
Modis, 2010]. A mechanism of hydroxyl radical production, which has been proposed, 
involves the reaction of superoxide radical with NO, forming peroxynitrite. Experiments 
with pure peroxynitrite have shown that it can decompose spontaneously into hydroxyl 
radicals and initiate the oxidative modification of both lipids and proteins. In vivo, the 
main sources of NO and anion superoxide remain inducible NO synthase (iNOS) and 
NADPH oxidase (NOX), respectively [Montezano and Touyz, 2011]. Consistent with 
these data, the ability of peroxynitrite to evoke LPO necessitates perfect coordination 
between iNOS and NOX expression and activity. Thus, the development of inhibitors of 
both enzymes could have substantial benefits in the treatment of various disease 
conditions, including osteoarthritis (OA), in which oxidative stress is increased. 
There is ample evidence that NO plays a key role in OA pathogenesis. Upon exposure to 
pro-inflammatory cytokines, OA cartilage produces excessive amounts of iNOS protein 
and its end-product NO [Amin et al., 1995;Castro et al., 2006]. High levels of 
nitrite/nitrate also have been found in synovial tissue from OA patients [McInnes et al., 
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1996]. It has been hypothesized that NO contributes to the development of arthritic 
lesions by inhibiting the synthesis of cartilage matrix macromolecules [Amin and 
Abramson, 1998] and by inducing chondrocyte death [Nakagawa et al., 2010], which 
could further contribute to extracellular matrix (ECM) reduction in OA. For example, 
anterior cruciate ligament transection in rabbits provokes chondrocyte apoptosis and 
NO production, events that can, however, be prevented by treatment with iNOS 
inhibitors [Hashimoto et al., 1998]. The suppression of NO generation also significantly 
curbs interleukin-1beta (IL-1β)-induced chondrocyte apoptosis [Chen et al., 2006] and 
reduces the progression of cartilage damage in experimental OA model in dog [Pelletier 
et al., 1998]. 
Like NO and reactive oxygen species (ROS), aldehydes are electrophiles that bind to 
nucleophilic groups of proteins, but their relatively longer half-lives make them 
candidates for the propagation of damage to neighbouring cells [Uchida, 2003]. 
Aldehyde levels increase significantly under intense oxidative stress, and this elevation 
is believed to contribute to the development of many pathological conditions [Poli et al., 
2008]. HNE, the principal α,β-unsaturated aldehyde formed from the LPO of both ω-3 
and ω-6 polyunsaturated fatty acids, is of specific interest in the present study as its 
formation is enhanced in synovial fluid from OA patients [Morquette et al., 2006]. In 
addition, growing evidence supports its role as a key modulator of catabolic and 
inflammatory mediators known for their involvement in the OA process [Morquette et 
al., 2006;Vaillancourt et al., 2008;El-Bikai et al., 2010]. The electrophilic nature of HNE 
makes it highly reactive with specific amino acids in proteins via Michael-type addition: 
the sulfhydryl group of cysteine (CYS) or lipoic acid, the -amino group of lysine (LYS), 
or the imidazole function of histidine (HIS) [Esterbauer et al., 1991;Wakita et al., 2011]. 
HNE homeostasis depends primarily on many factors, in addition to the magnitude of 
free radical production. Thus, conjugation to glutathione (GSH) by glutathione-s-
transferase A4-4 (GSTA4-4) is a major route of HNE elimination [Balogh and Atkins, 
2011]. It has been shown that GSTA4-4 metabolizes HNE with high catalytic efficiency 
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through its conjugation to GSH and has been suggested to be a major component of 
cellular defence against HNE toxicity [Sharma et al., 2011;Vaillancourt et al., 2008].  
While investigating the potential regulation of HNE levels in OA cartilage, we obtained 
data indicating that its production is regulated by NO generation. In this study, we tested 
the hypothesis that suppression of NO release with the iNOS inhibitor N-iminoethyl-L-
lysine (L-NIL) is a novel strategy to abrogate the LPO process and HNE generation in 
OA. 
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2.3 Materials and Methods 
 
Specimen selection and chondrocyte culture 
Discarded human post-surgery OA articular cartilage was obtained from OA patients 
(n=21, age 67±9 years mean±SEM) who underwent total knee arthroplasty. Informed 
consent was received from them to use their tissues for research purposes. All patients 
were evaluated by rheumatologists who followed American College of Rheumatology 
criteria [Altman et al., 1986]. The experimental protocols and research into human 
tissues were approved by the Research Ethics Board of Hôpital du Sacré-Cœur de 
Montréal.  
OA knee cartilage specimens were sliced and rinsed before chondrocyte extraction by 
sequential enzymatic digestion, as described previously [Morquette et al., 2006]. 
Cartilage samples were digested with 1 mg/ml of pronase (Sigma-Aldrich, Oakville, ON, 
Canada) for 1 h at 37ºC, and then with 2 mg/ml of type IV collagenase (Sigma-Aldrich) 
for 6 h in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Burlington, ON, 
Canada) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen), 
100 units/ml of penicillin and 100 μg/ml of streptomycin (Invitrogen). Chondrocytes 
were seeded at high density in culture flasks at 37ºC in a humidified atmosphere of 5% 
CO2/95% air until they were confluent and ready for experimentation.  
 
Experimental culture conditions 
OA chondrocytes (2x105 cells/cm2) were pre-treated with increasing concentrations of 
L-NIL (0-20 μM, Pfizer Canada Inc., Kirkland, QC, Canada) for 1 h, followed by incubation 
with or without either 1 ng/ml of IL-1β (Sigma-Aldrich), 10 μM 3-
morpholinosydnonimine (SIN, Sigma-Aldrich) or cytotoxic (20 μM) or non-cytotoxic (10 
μM) doses of HNE (Cayman Chemical, Ann Arbor, Ml, USA) for 24 h in 1% FBS-DMEM. 
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Prostaglandin E2 (PGE2), metalloproteinase-13 (MMP-13) and NO 
determination 
After chondrocyte incubation for 24 h, the medium was collected, and PGE2 and MMP-
13 levels were assessed by enzyme immunoassay (Cayman Chemical) and with enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA), 
respectively. Detection sensitivity was 9 and 8 pg/ml, respectively. All assays were 
performed in duplicate. Nitrite, a stable end-product of NO, was quantified in the 
supernatant according to a spectrophotometric method based on Griess reaction [Green 
et al., 1982]. Absorbance was measured with a micro-ELISA Vmax photometer (Bio-Tek 
Instruments, Winooski, VT, USA). 
 
Cell viability 
Chondrocyte viability was evaluated, as described previously [Mosmann, 1983], by 3- 
(4,5-dimethyl-thiazoyl)-2,5-diphenyl-SH-tetrazolium bromide (MTT) assay in 96-well 
plates (Fisher Scientific Company, Ottawa, ON, Canada) by incubating the cells with 0.5 
mg/ml MTT reagent (Sigma-Aldrich) for 15 min at 37°C. Then, 100 μl of solubilization 
solution (0.04 M HCl-isopropanol) was added, formazan salt was dissolved, and 
absorbance was read at 570 nm with the micro-ELISA Vmax photometer (Bio-Tek 
Instruments). 
 
iNOS activity assay  
Culture supernatants were removed and the cells were washed 3 times with phosphate-
buffered saline (PBS) and lysed by incubation with lysis buffer (40 mM Tris (pH 8.0), 
250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA, 10 mM β-glycerophosphate, 
10 mM NaF, 0.3 mM Na3VO4, 1 mM dithiothreitol) supplemented with protease inhibitor 
cocktail. Protein concentration of the cell lysates was measured by Bradford protein 
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assay (Bio-Rad Laboratories, Mississauga, ON, Canada). iNOS activity was assessed, as 
described previously [Sosroseno et al., 2011]. Briefly, 25 μg of chondrocyte lysate were 
incubated for 2 h at 37ºC in 100 μl of 20 mM Tris-HCl (pH 7.9) containing 5 μM 
tetrahydrobiopterin (BH4), 5 μM FAD, 1 mM dithiothreitol, 1 mM NADPH and 1 mM L-
arginine. All materials were purchased from Sigma-Aldrich. The reaction was then 
stopped by adding lactate dehydrogenase (10 U/ml), and NO levels were measured by 
the Griess method described above. Each assessment was repeated 3 times.  
 
Protein detection by Western blotting 
20 μg of total proteins of chondrocyte lysates, treated under the indicated conditions, 
were loaded for discontinuous 4-12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. They were then transferred electrophoretically onto nitrocellulose 
membranes (Bio-Rad Laboratories) for protein immunodetection and semi-quantitative 
measurement [Morquette et al., 2006]. The primary antibodies deployed were rabbit 
anti-human NOX component p47phox (p47 NOX, Cell Signalling Technology, Inc., 
Danvers, MA, USA), anti-HNE (Cayman Chemical), anti-nitrotyrosine (Cayman 
Chemical), anti-caspase-3 (EMD Biosciences, Inc., San Diego, CA, USA), and anti-human 
β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After serial washes, the 
primary antibodies were revealed by goat anti-mouse or anti-rabbit immunoglobulin G 
conjugated to horseradish peroxidase (Cell Signalling Technology, Inc.). 
Immunoreactive proteins were detected with SuperSignal blotting substrate (Pierce, 
Rockford, IL, USA) and exposed to Kodak X-Omat film (Eastman Kodak Company, 
Rochester, NY, USA). 
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Cellular level of HNE-protein adducts 
Total cellular levels of HNE-protein adducts were calculated in chondrocyte extracts 
under the indicated conditions by in-house ELISA [Morquette et al., 2006]. HNE-
modified bovine serum albumin (BSA) served as standard for HNE-protein adduct assay. 
 
Immunohistochemistry 
Human OA cartilage explants (~150 mg) were incubated for 1 h in the presence or 
absence of 10 mM L-NIL, followed by another incubation for 48 h in the presence of 1 
ng/ml IL-1β. The cartilage specimens were fixed in TissuFix #2 (Laboratoires Gilles 
Chaput, Montreal, QC, Canada) for 24 h, then embedded in paraffin. Sections (5 μm) of 
paraffin-embedded specimens were de-paraffinized in toluene, rehydrated in a reverse-
graded series of ethanol and pre-incubated with 0.25 units/ml chondroitinase ABC 
(Sigma-Aldrich) in PBS (pH 8.0) for 60 min at 37°C. The sections were subsequently 
washed in PBS, incubated in 0.3% Triton X-100 for 20 min, then placed in 3% hydrogen 
peroxide/PBS for 15 min. The slides were further incubated with blocking serum 
(Vectastain ABC kit, Vector Laboratories, Inc., Burlingame, CA, USA) for 60 min, after 
which they were blotted and overlaid with the primary antibody against HNE (1/200 
dilution, EMD Chemicals, Inc. Gibbstown, USA) or GSTA4-4 (1/500 dilution, Sigma-
Aldrich) for 18 h at 4°C in a humidified chamber. 
Each slide was washed 3 times in PBS (pH 7.4), stained by the avidin-biotin complex 
method (Vectastain ABC kit), and incubated in the presence of biotin-conjugated 
secondary antibody for 45 min at room temperature, followed by the addition of avidin-
biotin-peroxidase complex for 45 min. All incubations were undertaken in a humidified 
chamber at room temperature, and staining was developed with 3,3'-diaminobenzidine 
(DAKO Diagnostics Canada Inc., Mississauga, ON, Canada) containing hydrogen 
peroxide. The slides were counterstained with hematoxylin/eosin. 
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The sections were examined and photographed with a light Leica DM IRB microscope 
(Leica, Heerbrugg, Switzerland) equipped with a Leica DFC425 C camera (Leica). The 
presence of the antigen in cartilage was quantified by determining the number of 
chondrocytes that stained positive throughout cartilage thickness. Three sections from 
cartilage explants were examined, and the results were the means of positive 
chondrocytes counted in 3 light microscopic fields. The total number of chondrocytes 
and those staining positive in each field for the specific antigen were quantified. The 
final results were expressed as percentages of chondrocytes staining positive for the 
antigen (cell score), with the maximum score being 100%. Each slide was viewed by 2 
independent readers who were blinded to treatment group allocation.  
 
ROS measurement 
Intracellular ROS formation was measured with MitoSOX™ Red reagent (Invitrogen). 
Oxidation of MitoSOX™ Red reagent by superoxide produces red fluorescence, as 
described by Zhou et al. [Zhou et al., 2011]. Briefly, chondrocytes were seeded at a 
density of 2×104 cells/well in 96-well black plates (Becton Dickinson, San Jose, CA, USA). 
They were pre-treated with increasing concentrations of L-NIL 1 h before their exposure 
to IL-1β. Fluorescence was measured with a fluorescence plate reader at 510-nm 
absorption and 580-nm emission, and the data were expressed as relative MitoSOX™ 
Red fluorescence. To detect ROS in cells, the chondrocytes were transferred to 8-well 
culture chamber slides (Lab-Tek, Nalge Nunc International, Naperville, IL, USA), and 
incubated with MitoSOX™ Red reagent and 4',6-Diamidino-2-phenylindole (DAPI). ROS 
generation was then measured every 30 s for 15 min with a Leica DM IRB fluorescence 
microscope (Leica) equipped with a Leica DFC425 C camera (Leica). 
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Total GST activity 
Total GST activity was assessed with a commercial kit (Sigma-Aldrich) in 50 µg of 
chondrocyte extract. Briefly, the cells were homogenized on ice in 1 ml of buffer 
containing 180 mM KCl, 5 mM MOPS, and 2 mM EDTA, pH 7, and centrifuged for 10 min 
at 800 ×g at 4°C. The supernatants were subjected to enzyme assays after 10-min 
centrifugation at 6,000 ×g at 4°C. Protein levels were measured with a kit (Bio-Rad 
Laboratories) with BSA (Sigma-Aldrich) as standard. Activities were expressed in 
units/mg of proteins, where 1 unit was defined as the amount of enzyme catalyzing the 
conversion of 1 μmol substrate/min at 37°C. 
 
DNA fragmentation 
Cytoplasmic histone-associated DNA fragments were quantified with Cell Death 
Detection ELISAPLUS kits (Roche Applied Science, Laval, QC, Canada) according to the 
manufacturer's recommendations. Briefly, cultured chondrocytes (1x106 cells) were 
lysed with lysis buffer for 30 min and centrifuged at 200 g for 10 min. The supernatant 
and a mixture of anti-histone-biotin and anti-DNA-peroxidase were added to 
streptavidin-coated microplates and incubated for 2 h at room temperature. Absorbance 
was measured at 405 nm after inclusion of the substrate. 
 
Statistical analysis  
All values are expressed as means±SEM unless indicated otherwise. Multiple 
comparisons were made by 1-way ANOVA, as required, followed by the Bonferroni 
multiple-comparison post-test. Statistical comparisons were performed with GraphPad 
Prism software, version 4b (GraphPad Software, San Diego, CA, USA). In all tests, the 
criterion for statistical significance was p<0.05. 
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2.4 Results 
L-NIL prevents NO and iNOS production in OA chondrocytes 
In our first objective, we performed initial experiments to demonstrate that L-NIL 
prevents NO release and inhibits iNOS activity in isolated human OA chondrocytes. Cells 
were treated for 1 h with increasing doses of L-NIL (0–20 µM) and thereafter with or 
without 1 ng/ml IL-1β for 24 h. The addition of L-NIL significantly reduced IL-1β -
induced NO release (Fig. 1A) and iNOS activity (Fig. 1B) in a dose-dependent manner. At 
10 µM, L-NIL suppressed NO release by 80% (P<0.001) and iNOS activity by 90% 
(P<0.001). Collectively, these data confirm that L-NIL is a potent iNOS inhibitor. 
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Fig. 1. N-iminoethyl-L-lysine (L-NIL) reduces nitric oxide (NO) release and inducible nitric oxide synthase (iNOS) 
activity. Human osteoarthritis (OA) chondrocytes were treated with increasing L-NIL concentrations (0–20 µM) for 1 
h before incubation for 24 h in the presence of 1 ng/ml interleukin-1beta (IL-1β). a. NO release was assessed by the 
improved Griess method. b. iNOS activity was measured in the presence of arginine, BH4, and NADPH. Values 
represent the means_SEM of 3–4 separate experiments performed in duplicate. *P <0.05,**P <0.01,***P <0.001 
compared to untreated cells (control) (1% FBS); †P <0.01, ‡P <0.001 compared to IL-1b-treated cells. 
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L-NIL blocks HNE production through NO and peroxynitrite inhibition 
We and other research groups have reported the ability of NO to induce LPO via 
peroxynitrite generation [Morquette et al., 2006]. In the present study, we tested the 
hypothesis that NO inhibition suppresses peroxynitrite and, consequently, the 
production of HNE, a very reactive product of LPO. A previous study has shown that 
selective iNOS inhibition leads to reduction of HNE generation in renal cells (Noiri et al. 
2001). As illustrated in Figure 2A, the addition of 1 ng/ml IL-1β or 10 µM SIN, a donor 
of free radicals, induced a similar pattern of both NO release and HNE-protein adducts 
production. Compared to untreated cells, NO levels reached 15x2.5 nmol/2x105 cells 
(P<0.01) and 12x3 nmol/2x105 cells (P<0.05), and HNE attained 600±55 and 650±86 
pg/mg proteins (P<0.01) in the presence of SIN or IL-1β, respectively. Before testing the 
ability of L-NIL to inhibit HNE production, we investigated whether this drug blocks 
peroxynitrite generation. As expected, western blotting revealed that nitrotyrosine 
levels in nitrated proteins were lower in L-NIL-treated cells than in IL-1β treated cells 
(Fig. 2B). Interestingly, the addition of L-NIL at different dose levels also abolished IL-
1β-induced HNE production. Our ELISA and western blotting data (Fig. 2C,D) disclosed 
that L-NIL, at 10 µM, prevented HNE generation (P<0.01) in cell extracts from IL-1β -
treated OA chondrocytes. Afterwards, we tested the ability of L-NIL to prevent (or not) 
the IL-1 β -induced inactivation of HNEmetabolizing GST. As illustrated in Figure 2E, L-
NIL addition to cultured cells blocked GST inactivation by IL-1β (P<0.05). Taken 
together, these findings strongly suggest that HNE production is linked, at least in part, 
to NO release and iNOS activation. L-NIL could be considered an interesting tool to 
abrogate both NO generation and LPO in OA chondrocytes. It also prevented impairment 
of redox status in IL-1β -treated cells.  
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Fig. 2. N-iminoethyl-l-lysine (L-NIL) suppresses the lipid peroxidation product 4-hydroxynonenal (HNE).  
a: Confluent human osteoarthritic (OA) chondrocytes were treated with either 10 µM SIN (a NO donor) or 1 ng/ml 
IL-1β for 24 h. NO and HNE generation was assessed by the improved Griess method or ELISA, respectively. (b-e) 
Human OA chondrocytes were treated with increasing doses of L-NIL (0–10 µM) for 1 h, followed by incubation for 
24 h in the presence or absence of 1 ng/ml IL-1b. The cells were then lysed and analyzed. Nitrated protein levels were 
evaluated by western blotting (b), HNE/protein adducts were quantified by ELISA (c) and analyzed by western blotting 
(d), and GST activity was assessed with a commercial kit (e). The NO, HNE/protein adduct and GST activity results are 
expressed as nmol/2x105 cells, pg/mg proteins or mU/mg proteins, respectively, and represent the means_SEM of 
four independent experiments performed in duplicate.*P <0.05,**P <0.01,***P <0.001 compared to untreated cells 
(1% FBS); #P <0.05, †P <0.01 compared to IL-1b-treated cells alone.  
0 SIN (10 μM) βIL-1  (1 ng/mL)
0
5
10
15
20
NO HNE
1000
800
600
400
200
0
 N
itr
ic
 o
xi
de
 co
nc
en
tr
a
on
(n
m
ol
/2
x1
0
5  c
el
ls)
HN
E/protein adducts
(pg/m
g proteins)
0 0.1 1 5 10
0
40
80
120
HN
E/
pr
ot
ei
n 
ad
du
ct
s
(p
g/
m
g 
pr
ot
ei
ns
)
IL-1β (1 ng/ml)
L-NIL concentraon (μM)
40
0
80
120
160
200
GS
T 
ac
v
ity
(m
U/
m
g 
pr
ot
ei
ns
)
0 0.1 1 5 10
IL-1β (1 ng/ml)
L-NIL concentraon (μM)
# #
IL-1β (1 ng/ml)
ni
tr
at
ed
 p
ro
te
in
s
L-NIL
kDa
172
0 0 1 5 10 - μM 
110
79
62
48
36
24
IL-1β (1 ng/ml)
H
N
E/
pr
ot
ei
n 
ad
du
ct
s
L-NIL
kDa
172
0 0 1 5 10 - μM 
110
79
62
48
36
24
a.
b.
c.
e.
d.
59 
Immunohistochemistry of HNE and GSTA4-4 
Chondrocytes staining positive for HNE and GSTA4-4 were found in OA cartilage. 
Compared to the controls (Fig. 3A), chondrocytes stained positive for increased HNE, 
which reached 61% (Fig. 3B, P<0.01) in IL-1β-treated OA cartilage. However, 10 μM L-
NIL significantly prevented IL-1β -induced HNE production in OA cartilage (Fig. 3C, 
P<0.05). Furthermore, compared to the controls (Fig. 3D), chondrocytes stained 
positive for decreased GSTA4-4, which reached 14%  (Fig. 3E, P<0.01) in IL-1β-treated 
OA cartilage. However, 10 μM L-NIL significantly abolished IL-1β inhibition of GSTA4-4 
expression in OA cartilage (Fig. 3F, P<0.05). Altogether, our results confirm that the 
iNOS inhibitor L-NIL attenuates oxidative stress and restores redox status by reducing 
HNE generation and reinstating GSTA4-4 expression in cartilage explants. 
 
60 
 
Fig. 3. Immunohistochemistry of HNE and GSTA4-4. Representative section showing 4-hydroxynonenal (HNE) (A–
C) and GSTA4-4 (D–F) immunostaining in superficial zones of articular cartilage from human osteoarthritis (OA) 
cartilage explants treated or not for 1h with 10 µM L-NIL, followed by another incubation for 24 h with 1 ng/ml IL-1β 
(original magnification x100). The number of chondrocytes staining positive for HNE and GSTA4-4 were evaluated 
and analyzed as described in Materials and Methods section. **P <0.01 compared to untreated OA cartilage (control); 
#P <0.05 compared to IL-1β-treated cells.   
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L-NIL abolishes ROS generation and p47 NOX phosphorylation 
It is well-documented that the generation of ROS, such as superoxide anion and hydroxyl 
radical, plays an important role in initiating LPO. Thus, the purpose of this part of the 
present study was to investigate whether L-NIL’s capability to inhibit HNE production 
is attributed to its ability to also prevent ROS generation. To do so, OA chondrocytes 
were pre-treated with 10 μM L-NIL for 1 h, followed by exposure to 1 ng/ml IL-1β for 
24 h. ROS generation was observed by fluorescence microscopy and then quantified 
with MitoSOX™ Red reagent. As illustrated in Figure 4B, elevated ROS levels were 
detected by fluorescence microscopy in OA chondrocytes treated with 1 ng/ml IL-
1β  compared to untreated cells (Fig. 4A). Interestingly, ROS production was quenched 
by L-NIL treatment (Fig. 4C). DAPI staining, which reveals nuclei, was employed to 
assess their number and to examine gross cell morphology. Quantitatively, our data 
indicated that relative MitoSOX™ Red fluorescence was higher in 1 ng/ml IL-1β-treated 
cells and reached 220±36 (P<0.05) (Fig. 4D). However, when the cells were treated with 
both 1 ng/ml IL-1β and 10 μM L-NIL, relative MitoSOX™ Red fluorescence decreased 
significantly to 121±16 (P<0.05) (Fig. 4D). Finally, an additional experiment was 
performed to determine the possible ability of L-NIL to inhibit p47 NOX 
phosphorylation, a ROS-generating enzyme. Western blotting analysis showed that 10 
μM L-NIL prevented IL-1β-induced p47 NOX phosphorylation (Fig. 4E). Collectively, our 
data indicated that suppression of ROS production and ROS-generating NOX by the 
selective inhibitor of iNOS had a significant LPO outcome. 
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Fig 4. N-iminoethyl-L-lysine (L-NIL) suppresses reactive oxygen species (ROS) generation and NADPH oxydase 
(NOX) phosphorylation. (A-C) Confluent human osteoarthritic (OA) chondrocytes were treated for 1 h with 10 μM L-
NIL, followed by incubation for 24 h in the presence or absence of 1 ng/ml IL-1β. ROS generation was revealed by 
fluorescence microscopy with MitoSOX™ Red reagent. (D & E) Cells were treated for 1 h with increasing 
concentrations of L-NIL (0-10 μM), followed by incubation for 24 h in the presence or absence of 1 ng/ml IL-1β. (D) 
ROS generation was quantified in cell extracts with MitoSOX™ Red reagent. ROS levels were expressed as relative 
MitoSOX™ Red fluorescence. (E) Total (p47) and phosphorylated (pp47) NOX protein were analyzed by Western 
blotting in protein extracts from human OA chondrocytes treated as described above. The data are means±SEM of 4 
independent experiments. *P<0.05 compared to untreated cells (control) (1% FBS); #P<0.05 compared to IL-1β-
treated cells alone. 
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HNE-induced cell death is blocked by L-NIL 
We reported that HNE up to 10 μM did not alter cell viability, but 20 μM HNE was 
cytotoxic and significantly decreased cell viability by approximately 50% [Vaillancourt 
et al., 2008]. We evaluated the ability of L-NIL to reduce HNE cytotoxicity in cultured 
chondrocytes. Cell viability was assessed with MMT reagent. After 24 h of incubation, 
pre-treatment with 5 and 10 μM L-NIL for 1 h before adding 20 μM HNE to the culture 
media prevented HNE-induced cell death (Fig. 5A) as well as markers of apoptosis, 
including caspase-3 activation (Fig. 5B) and DNA fragmentation (Fig. 5C). These data 
suggest that L-NIL probably prevents HNE’s effects through direct HNE quenching. 
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Fig 5. 4-Hydroxynonenal (HNE)-induced cell death is blocked by L-NIL. Chondrocytes were pre-incubated for 1 h 
with or without increasing doses of L-NIL (0-10 μM) followed by another incubation for 24 h with a cytototoxic HNE 
dose (20 μM). (A) Cell viability was evaluated by MTT assay. (B) Activation of caspase-3 was determined by Western 
blotting. (C) Cytoplasmic histone-associated DNA fragments were quantified with a kit. The data, expressed as % of 
untreated cells for cell viability and DNA fragmentation, are the means±SEM of 4 independent experiments. *P<0.05, 
**P<0.01 compared to untreated cells (1% FBS); #P<0.05 compared to HNE-treated cells alone. 
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HNE-induced PGE2 and MMP-13 production are abrogated by L-NIL 
This part of our study was designed to verify L-NIL’s ability to attenuate HNE-evoked 
the production of inflammatory and catabolic mediators known to be involved in 
cartilage damage, such as PGE2 and MMP-13, respectively. When the cells were treated 
with non-cytotoxic doses of HNE (at 10 μM) [Vaillancourt et al., 2008], L-NIL prevented 
HNE-induced PGE2 (Fig. 6A) and MMP-13 (Fig. 6B) release. At 10 μM, L-NIL reduced 
PGE2 and MMP-13 levels by 55 (P<0.01) and 60% (P<0.05), respectively. Pro-MMP-13 
is shown here because we have already previously shown both pro and active MMP-13 
induction by HNE (Morquette et al. 2006). In fact, active MMP-13 showed a 2,5 fold 
increased when treated with 10 µM/ml of HNE when compared with untreated cells 
(Morquette et al. 2006). 
 
 
Figure 6: N-iminoethyl-L-lysine (L-NIL) prevents 4-hydroxynonenal (HNE) induction of prostaglandin E2 (PGE2) and 
metalloproteinase-13 (MMP-13). Human osteoarthritic (OA) chondrocytes were treated for 1 h with different doses 
of L-NIL (1-10 μM) before incubation with non-cytotoxic (10 μM) doses of HNE for 24 h. Supernatants were collected, 
and PGE2 (A) and MMP-13 (B) levels were measured with commercial enzyme immunoassay (EIA) or enzyme-linked 
immunosorbent assay (ELISA) kits, respectively. The data, expressed as ng/ml for PGE2 and MMP-13 protein, 
represent the means±SEM of 4 independent experiments. *P<0.05, **P<0.01, ***P<0.001 compared to untreated 
cells (1% FBS); #P<0.05, †P<0.01 compared to HNE-treated cells alone. 
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2.5 Discussion 
Articular cartilage is believed to be a major source of NO in OA joints and synovial fluid 
[Pelletier et al., 1998]. Previous in vitro studies have shown that chondrocytes produce 
NO as a key metabolite in response to stimuli such as mechanical stress, IL-1 , IL-1β 
and lipopolysaccharides (LPS) [Abramson, 2008]. In addition, iNOS is up-regulated in 
OA chondrocytes, resulting in excess NO and perpetuating the release of inflammatory 
cytokines and other catabolic processes. NO inhibits both proteoglycan and collagen 
synthesis, activates MMPs, mediates chondrocyte apoptosis and promotes chondrocyte 
inflammatory responses [Abramson, 2008]. These findings add to the prevailing 
hypothesis that NO is a pro-inflammatory and pro-apoptotic factor that, when present 
in excess, is detrimental to the joints and contributes to OA pathogenesis. A number of 
iNOS inhibitors have been developed to prevent NO production in OA joint tissues. 
Among them, L-NIL is a potent and selective iNOS inhibitor. However, the detrimental 
effects of NO in OA cartilage have been challenged by a number of reports showing that 
NO may inhibit pro-inflammatory responses by preventing nuclear factor-kappa B (NF-
κB) transactivation in cultured chondrocytes [Rosa et al., 2008]. In addition, under some 
conditions, exogenous NO can stimulate collagen synthesis in cultured human tendon 
cells [Xia et al., 2006]. In vivo, Veihelmann et al. [Veihelmann et al., 2001] demonstrated 
that NO production by iNOS has anti-inflammatory effects in experimental arthritis, by 
mediating a reduction of leukocyte adhesion and infiltration. Further research may help 
to elucidate a potential role for NO-donating agents in OA management. 
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In the present study, our observations provided the impetus for a novel therapeutic 
target of the iNOS inhibitor L-NIL, namely, ROS and the LPO product HNE, in OA. In our 
in vitro experiments, NO generation and oxidative stress were induced in human OA 
chondrocytes treated with IL-1β or SIN (a NO donor). First, we obtained data showing 
that L-NIL significantly reduced both IL-β-evoked NO and peroxynitrite release as well 
as iNOS activity in human OA chondrocytes. These findings are in agreement with 
numerous reports indicating that this drug is a potent inhibitor of NO production via 
iNOS inactivation in OA in vitro and in vivo. In cartilage explants, L-NIL markedly curbed 
chondrocyte apoptosis by obviating NO generation [Pelletier et al., 2001]. In an 
experimental dog model of OA, oral administration of L-NIL decreased NO production, 
resulting in marked reductions of major catabolic factors, such as MMPs, IL-1β and 
peroxynitrite, as well as diminution of cyclooxygenase-2 (COX-2) expression [Pelletier 
et al., 1999]. Macroscopically, L-NIL diminished cartilage lesion size by approximately 
50% on both condyles and plateaus. The histological severity of both cartilage lesions 
and synovial inflammation was significantly curtailed in L-NIL-treated dogs [Pelletier et 
al., 1998]. However, these data contrast with those reported by McCartney-Francis et al. 
[Cartney-Francis et al., 2001] who demonstrated that L-NIL administration exacerbated 
the chronic inflammatory response, as reflected by profound tissue destruction and 
bone and cartilage losses. Altogether, such findings warrant caution as to the possible 
utility of NOS inhibitors in OA therapy, necessitating enhanced knowledge and 
understanding of the (patho)physiological role of iNOS in OA.  
 
Second, recognizing the important role of LPO products in OA, we tested the hypothesis 
that inhibition of NO generation in OA chondrocytes culminates in the prevention of 
HNE generation, a very reactive LPO product. Our findings revealed, for the first time, 
that L-NIL blocked IL-1β-induced HNE-protein adduct accumulation in isolated 
chondrocytes and cartilage explants, indicating that NO is involved in LPO. It has been 
established that NO can promote LPO via peroxynitrite generation. Over the last few 
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years, reactive LPO products have been at the center of the pathophysiological scene of 
OA disease. In a previous report, we documented a significant increase of endogenous 
HNE levels in its adducted form in synovial fluid samples from OA patients compared to 
control subjects [Morquette et al., 2006]. These data are consistent with the findings of 
Grigolo and colleagues [Grigolo et al., 2003] and Shah and colleagues [Shah et al., 2005], 
who observed higher levels of both malondialdehyde and HNE in human articular 
tissues from OA patients in comparison to healthy subjects. In addition, incubation of 
isolated OA chondrocytes with tumour necrosis factor-alpha or NO donors (e.g. SIN) 
provided direct evidence implicating these mediators in HNE production, given that all 
of them were able to increase HNE/protein adduct levels in cellular extracts [Morquette 
et al., 2006]. Like NO, HNE has the ability to activate a panoply of factors known for their 
involvement in OA. For example, in OA cartilage, HNE can provoke transcriptional as 
well as post-translational modifications of collagen type II (Col II) and MMP-13, 
resulting in cartilage ECM degradation [Morquette et al., 2006]. In addition, HNE can 
selectively stimulate COX-2 expression via activating transcription factor/cAMP 
response element and inhibit iNOS expression via NF-κB inactivation in human 
chondrocytes [Vaillancourt et al., 2007]. More recently, we demonstrated that HNE-
binding to Col II culminates in multiple abnormalities in chondrocyte phenotype and 
function, indicating its contribution to alteration of cell-ECM interaction in OA [El-Bikai 
et al., 2010]. Taken together, and in conjunction with the fact that L-NIL abolishes HNE 
generation and restores redox status, these findings open new avenues for this drug in 
the treatment of OA patients.  
 
To determine the impact of L-NIL treatment on HNE-metabolizing enzymes in 
chondrocytes, we conducted additional experiments to verify its effect on GST activity 
in chondrocytes. As predicted, our data showed that L-NIL prevented IL-1β-induced GST 
inactivation, suggesting normalization of redox status by its administration. Our results 
are in agreement with other observations indicating that NO-Derived Oxidants inhibit 
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GST expression(Wong et al. 2001). The transcriptional suppression of GST by IL-1β is 
known to be mediated by hepatic nuclear factor [Ng et al., 2007]. Furthermore, our 
findings strongly suggest that GST inactivation after IL-1β addition could be attributed, 
in part, to NO generation. The decrease in total GST activity in cartilage can compromise 
tissue defence against HNE and other electrophiles. Several lines of evidence have 
revealed that GST is a target of nitrosylation and oxidation by NO and ROS, respectively 
[Cesareo et al., 2005;Letelier et al., 2010]. While multiple GST isoforms exist with 
distinct catalytic properties, structural observations have indicated that most cytosolic 
GST isoforms contain a highly-conserved tyrosine (TYR) residue which is crucial for 
their catalytic function. It has been shown that thiol group modification at CYS residues 
affects GST’s enzymatic activity. Therefore, NO donor-mediated GST inactivation may 
possibly arise through interaction with either CYS or TYR residues, or both. It has also 
been reported that hydrogen peroxide leads to the formation of intra- or inter-subunit 
disulfide bonds between certain CYS residues within GST amino acid sequences, 
inactivating this enzyme [Letelier et al., 2006].  
 
For the first time in the literature, our data suggest that NO compromises the 
detoxification abilities of cartilage and renders it more vulnerable to oxidant injuries 
through down-regulation of GST activity. GSTA4-4, an isoform of GST, is one of the most 
important pathways for HNE detoxification by catalyzing the conjugation of this 
aldehyde with GSH [Awasthi et al., 2004;Balogh and Atkins, 2011]. We have reported 
recently that gene silencing of GSTA4-4 by small interfering RNA augments the cytotoxic 
effect of HNE [Vaillancourt et al., 2008]. In contrast, the over-expression of this enzyme 
in chondrocytes offers significant protection against HNE-induced cell cytotoxicity. Our 
unpublished data show that GSTA4-4 over-expression in OA chondrocytes blocks 
different HNE-induced factors known to be involved in the OA process, including MMP-
13 and COX-2 expression. Furthermore, we found, in the present study, that L-NIL 
prevents HNE-induced apoptosis as well as MMP-13 and PGE2 production. The 
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molecular mechanism underlying HNE-induced apoptosis as well as PGE2 and MMP-13 
was reported by us previously [Vaillancourt et al., 2008;Vaillancourt et al., 
2007;Morquette et al., 2006]. These data can be explained by decreased HNE 
bioavailability via GST metabolism or perhaps via [HNE/L-NIL] adduct formation. As 
proposed in Figure 7, we can speculate that HNE trapping by L-NIL occurs via its LYS 
residue. The α,β double bond of HNE is believed to react spontaneously via Michael-type 
addition with the sulfhydryl group of CYS, the ε-amino group of LYS, and the imidazole 
function of HIS, and these adducts are currently considered as the predominant 
modification of proteins by HNE [Poli et al., 2008].  
 
Furthermore, besides the upstream products of LPO, L-NIL abolished IL-1β-induced ROS 
generation and p47 NOX phosphorylation in chondrocytes. Two hypotheses could 
explain these data. The first is based on findings in the literature indicating that NO is 
important in ROS generation via NOX up-regulation. Compelling but controversial 
studies have investigated the role of NO in the regulation of ROS production via NOX. 
Our data are in agreement with the observations of Kaur et al. [Kaur et al., 2004] who 
reported NOX induction by NO in IL-1β-treated human coronary artery smooth muscle 
cells. Owayed and colleagues [Owayed et al., 2008] noted an increase in the activity and 
transcriptional regulation of NOX-1 and gp91phox by NO in peripheral blood 
lymphocytes from asthmatic patients. However, others studies presented additional 
evidence that prolonged exposure of human endothelial cells to NO donors causes 
sustained suppression of superoxide production via inhibition of NOX activity through 
S-nitrosylation of p47phox [Harrison et al., 2010;Selemidis et al., 2007]. Therefore, the 
second hypothesis is based on the ability of NOS to generate ROS (Fig. 7). The enzyme 
can produce large amounts of ROS when deprived of its critical co-factor BH4 or its 
substrate L-arginine. Limitation of substrate availability leads to iNOS uncoupling and 
ultimately to ROS formation [Gielis et al., 2011]. Increased iNOS expression in the 
presence of limited substrate availability may result in iNOS uncoupling [Otani, 
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2009;Wells and Holian, 2007], thus potentially promoting ROS formation and, 
consequently, LPO. It has been reported that iNOS inhibition by N- (3- 
(aminomethyl)benzyl)acetamidine attenuates superoxide anion formation and 
oxidative damage [Heusch et al., 2010]. In this state, often referred to as NOS 
uncoupling, electron flow through the enzyme culminates in reduced molecular oxygen 
at the prosthetic heme site rather than NO formation [bu-Soud et al., 1994]. 
In summary, our study demonstrated that L-NIL inhibited NO and ROS generation and, 
consequently, LPO in OA chondrocytes. Moreover, L-NIL administration was shown to 
play a role in redox status normalization via the prevention of GST inactivation in these 
cells. Our findings suggest that L-NIL may represent a new therapeutic approach to 
chronic autoimmune arthritis. An overview of the different mechanisms mediating HNE 
production and L-NIL action is proposed (Fig. 7). 
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Figure 7: Overview of different mechanisms mediating 4-hydroxynonenal (HNE) production and  
N-iminoethyl-L-lysine (L-NIL) action. Superoxide anion could be produced by NADPH oxidase (NOX), under NO effect, 
or by NOS uncoupling. NO mainly interacts with superoxide anion to form peroxynitrite, which further induces lipid 
peroxidation (LPO). The iNOS inhibitor L-NIL has the ability to abolish HNE levels via (i) NO reduction, (ii) possible 
[HNE/L-NIL] adduct formation, and (iii) GST up-regulation. 
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CHAPTER 3: Discussion 
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NO as therapeutic target 
For a years now, a large number of studies have investigated NO as a therapeutic target 
in pathologies involving inflammation (Ricciardolo & Sterk 2004; McCartney-Francis & 
Allen 1993; Pacher et al. 2007; Hansel et al. 2003). NO has been of particular interest in 
articular pathologies, more specifically OA, due to its heightened levels in the joint fluids 
of patients with this disease (Abramson 2008). This phenomenon has also been 
observed in experimental animal OA model (Pelletier et al. 1998). NO overproduction in 
OA chondrocytes is most likely the result of a snowball effect involving biomechanical 
stress and redox signals followed by inflammation. Initial stress prompts NO and 
proinflammatory cytokine production, which in turn activates more NO production, 
leading to a positive feedback loop. Furthermore, NO has been shown to cause MMP 
activation, inhibition of proteoglycan and collagen synthesis as well as apoptosis and 
inflammatory responses in chondrocytes (Abramson 2008). All these make NO an 
interesting target in OA treatment/prevention. This is why we have focused this study 
on the reduction of NO production through selective inhibition of its main source, iNOS, 
by L-NIL. 
 
iNOS inhibition modulates LPO product generation 
To imitate knee OA conditions, we started off by inducing NO generation and oxidative 
stress in human OA chondrocytes by treating them with either IL-1β or SIN (a NO 
donor). Our results showed a significant increase in NO and HNE/protein adducts with 
both IL-1β and SIN. We decided to continue investigations with IL-1β treatment since it 
is naturally present in elevated levels in OA articular cartilage.  Afterwards, we needed 
to make sure that our selective iNOS inhibitor, L-NIL, really did prevent NO production 
and iNOS activation. The data we obtained concurred with previous reports and 
confirmed L-NIL’s potent ability to suppress both NO release and iNOS activity. Next, we 
showed that L-NIL can block peroxynitrate generation by observing a decreased in 
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nitrotyrosine protein adducts. Since ONOO- it is a key actor in LPO, this indicated that 
we could also expect a drop in HNE production. Further investigation indeed showed a 
significant reduction in HNE/protein adduct accumulation in isolated chondrocytes and 
cartilage explants. This was an interesting find since our laboratory has previously 
shown HNE’s implication in increased inflammation leading to matrix degradation and 
cell death(Vaillancourt et al. 2008; Morquette et al. 2006). Study into the effects of iNOS 
inhibition on HNE metabolism showed that addition of L-NIL almost completely 
abolished IL-1β ability to supress GST, thus making it available for HNE detoxifying. This 
indicates that NO might play a role in IL-1β induced inactivation GST. In fact, some 
studies have revealed that GST is a target of nitrosylation and oxidation by NO and ROS, 
respectively (Cesareo et al. 2005; Letelier et al. 2010). 
 
Inhibition of iNOS blocks pathophysiological effects of HNE 
In the present study, we also investigated the consequences of L-NIL addition on three 
of the most problematic pathophysiological effects of HNE: cell death, MMP-13 and PGE2 
production. We found that OA chondrocyte treatment with  
L-NIL prevented all three. This did not come as a surprise since we had already 
established a decrease in HNE/protein adducts. It is probable that an increase in HNE 
metabolism by now available GST, thus a decrease in HNE bioavailability, is mainly 
responsible for this protective effect of L-NIL. It is however also possible that HNE might 
be unavailable due to [HNE/L-NIL] adduct formation. Similar “trapping” phenomenon 
of HNE by carnosine has already been described by our laboratory (El-Bikai et al. 2010).  
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L-NIL reduces oxidative stress by preventing ROS generation  
Finally, we wondered if L-NIL had an effect on ROS generation because of their 
implication in both LPO and GST inactivation. ROS levels were found to be abolished by 
L-NIL. This might be caused by suppression of NOX activation, which has been shown to 
be induced by NO in IL-1β-treated human coronary artery smooth muscle cells (Kaur et 
al. 2004). ROS production can also be attributed to iNOS uncoupling through the 
increase expression of iNOS in OA chondrocytes (Gielis et al. 2011; Otani 2009; Wells & 
Holian 2007). It is thus also possible that the decrease in ROS observed after L-NIL 
addition is directly caused by the decrease in iNOS expression. 
 
Though all of our data seem promising, it is important to keep in mind that McCartney-
Francis et al. reported that L-NIL administration exacerbates the chronic inflammatory 
response, as reflected by profound tissue destruction and bone and cartilage losses 
(McCartney-Francis et al. 2001). Altogether, such findings warrant caution as to the 
possible utility of NOS inhibitors in OA therapy, necessitating better understanding of 
the role of iNOS in OA.  
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CHAPTER 4: Conclusion 
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Because NO plays such a prominent role in OA, we have studied the outcome of 
selectively inhibiting the enzyme most responsible for its production in OA patients, 
namely iNOS. To do so, we investigated how L-NIL affected several key aspects of OA 
pathophysiology. Doing so, we have demonstrated that L-NIL inhibited ROS generation 
and consequently LPO in OA chondrocytes. Since it prevented LPO, it also abolished HNE 
production. Moreover, L-NIL administration was shown to play a role in redox-status 
normalization via preventing GST inactivation in these cells. This probably explains how 
addition of L-NIL greatly reduced pathological effects of HNE such as cell death as well 
MMP-13 and PGE2 upregulation. Another theory is that L-NIL might be trapping HNE by 
forming an L-NIL/HNE adducts as carnosine does (see Figure 20). 
 
Either way, these findings suggest that L-NIL may represent a new therapeutic 
approach to the treatment of chronic autoimmune arthritis. Further investigation 
should be done to better understand L-NIL’s mechanism of action and potential side 
effect in vivo. Tough Pelletier and al. have done an OA dog model in vivo study with oral 
administration(Pelletier et al. 1998); it could be interesting to see how local injection 
might provide a more specific result with a much lower likeliness to have a systemic 
impact. 
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Figure 20. Overview of L-N6- (l-iminoethyl)lysine effect on 4-hydroxynonenal (HNE) 
Overview of different mechanisms mediating 4-hydroxynonenal (HNE) production and  
N-iminoethyl-L-lysine (L-NIL) action. Superoxide anion could be produced by NADPH oxidase (NOX), under NO effect, 
or by NOS uncoupling. NO mainly interacts with superoxide anion to form peroxynitrite, which further induces lipid 
peroxidation (LPO). The iNOS inhibitor L-NIL has the ability to abolish HNE levels via (i) NO reduction, (ii) possible 
[HNE/L-NIL] adduct formation, and (iii) GST up-regulation (Bentz et al. 2012). 
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